Subject Index

A

ABDV (adriamycin, bleomycin, DTIC, and vinblastine)
alternating with MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) and radiotherapy for advanced Hodgkin's disease, 1217
versus MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) in the treatment of Hodgkin's disease, 205
Acrolein, biologic activity in vitro compared to other derivatives and possible metabolites of cyclophosphamide, 373
Actinomycin D (NSC-3053)
combined with cyclophosphamide and vincristine in the treatment of advanced sarcomas: a comparative clinical trial with other single-agent and combination therapy, 1385
combined with cytosine arabinoside: use of cell-cycle information in the preparation of drug combinations, 1813
combined with DTIC and BCNU in the treatment of advanced malignant melanoma, 33
combined with DTIC and BCNU in the treatment of malignant melanoma, 205
in vitro response of mammalian cells to drug-induced potentially lethal and sublethal damage, 1799
Limulus amebocyte lysate assay used to detect the presence of bacterial endotoxin in various lots of, 9
single-dose, pharmacokinetically based phase I–II study of, 289
Adenocarcinoma 755 (*see also* Tumor systems in animals)
effects on macromolecular synthesis in cell culture and evidence for alkylating activity, 1317
studies with 2,5-piperazinedione, 3,6-bis(5-chloro-2-piperidyl)-, dihydrochloride: kinetic and biologic effects in cultured cells, 1307
Adrenalectomy *see* Surgery
Adriamycin (NSC-123127)
activity of anthracyclines, particularly cinerubin A, against a subline of P388 leukemia resistant to, 99
alone and combined with DTIC in the treatment of various sarcomas, 199
alone versus 5-FU combined with cyclophosphamide in the treatment of metastatic prostate cancer, 115
amelioration of toxicity by α-tocopherol (vitamin E), 961
arrested and cycling CHO cells as a kinetic model: studies with, 1829
cardiotoxicity, echocardiographic evaluation of, in children, 1281
cardiotoxicity, noninvasive monitoring of, by "Sphygmo-Recording" of the pulse wave delay (QK_1 interval), 1239
and CCNU in advanced breast cancer, 1687
combined with bleomycin and vinblastine for advanced testicular tumors, 953
combined with bleomycin, vinblastine, and DTIC (ABVD) in the treatment of Hodgkin's disease, 205
combined with CCNU and hexamethylmelamine in the treatment of lung cancer, 269
combined with *Corynebacterium parvum* in experimental tumor systems, 823
combined with cyclophosphamide, methotrexate, and procarbazine (CAMP) in the effective treatment of metastatic non-oat cell lung carcinoma, 1225
combined with DTIC against B16 melanoma and C3H mammary adenocarcinoma, 135
combined with DTIC and vincristine in the treatment of advanced sarcomas: a comparative clinical trial with other single-agent and combination therapy, 1385
combined with DTIC in the treatment of soft tissue sarcomas, 205
combined with vinblastine and procarbazine in a phase II study of small cell carcinoma of the lung, 1263
compared to activity of cinerubin A against transplanted animal tumors, 99
in vitro response of mammalian cells to drug-induced potentially lethal and sublethal damage, 1799
Limulus amebocyte lysate assay used to detect the presence of bacterial endotoxin in various lots of, 9
phase II trials, combined with cyclophosphamide in the treatment of various solid tumors, 77
phase II trial of, combined with methotrexate and 5-FU in the treatment of lung adenocarcinoma, 623
pigmentation of the tongue after treatment with, 1402
prevention by coenzyme Q_{10} of the inhibition of coenzyme Q_{10} enzymes by, 223
proliferative character and growth modes of neoplastic disease in animals as determinants of chemotherapeutic efficacy, 1761
rapid analytic method for, and metabolites in human plasma by a thin-film fluorescence scanner, 1611
response of metastatic malignant carcinoid tumor to, 273
studies of, using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity, 813
in the treatment of far-advanced lung cancer, 939
used sequentially with cyclophosphamide, vincristine, bleomycin, methotrexate, and methyl-CCNU in the treatment of advanced, recurrent, squamous cancer of the head and neck, 103
plus vincristine and bleomycin compared to ICRF-159 alone in non-small cell lung cancer, 947
plus vincristine and bleomycin compared to VP-16-213 alone and vincristine plus cyclophosphamide and methotrexate for advanced small cell cancer, 949

Adverse reactions *see* Toxic reactions in man
Aldophosphamide
pharmacokinetics of, in vivo, 415
synthesis, characterization, and comparison with "Hohorst's aldophosphamide," 317
Aminopterin (NSC-739), competitive dehydrofolate reductase binding assay of, 615
Anhydro-ara-5-fluorocytidine (2,2′-anhydro-1-β-D-arabinofuranosyl-5-fluorocytosine) (NSC-166641)
compared to cytosine arabinoside in the treatment of murine brain tumor, 875
effects on ultrastructure of submaxillary salivary glands from mice treated with, compared to effects of cytosine arabinoside and cyclocytidine, 881
phase I study of weekly administration of, 281
Antibiotics (*see also* specific drugs), yeast mutants with distorted cell membranes as tests in the screening for, 637
5-Arylpyrimidine antifolates (*see* DDMP)
L-Asparaginase (NSC-109229)
activity in acute nonlymphocytic leukemia, 966
combined with vincristine and prednisone, in a study of cytosine arabinoside synchronization of leukemic cells, for remission induction in advanced acute leukemia in children, 591
comparative experimental evaluation of immunodepressive and toxic effects of, from *Escherichia coli* and from *Erwinia carotovora*, 255
Limulus amebocyte lysate assay used to detect the presence of bacterial endotoxin in various lots of, 9
L-Asparagine synthetase, inhibitors of, in vitro, 1493
5-Azacytidine (NSC-102816)
dihydro-5-azacytidine hydrochloride, a biologically active and chemically stable analog of, 1671
Limulus amebocyte lysate assay used to detect the presence of bacterial endotoxin in various lots of, 9
symptomatic hypophosphatemia secondary to therapy for acute nonlymphocytic leukemia, 1400

B

Bacillus Calmette-Guérin
plus BACON in the treatment of head and neck cancer, 535
immunotherapy in combination with DTIC in the treatment of malignant melanoma, 177
as treatment for malignant melanoma, 159
BACON (bleomycin, adriamycin, CCNU, vincristine, and mechlorethamine), alone versus BACON plus Bacillus Calmette-Guérin in the treatment of head and neck cancer, 535
BCNU (NSC-409962)
in combinations with DTIC plus vincristine and DTIC plus hydroxyurea in the treatment of metastatic malignant melanoma, 601
combined with DTIC and actinomycin D in the treatment of malignant melanoma, 205
combined with DTIC and vincristine, and actinomycin D and DTIC in the treatment of advanced malignant melanoma, 33
combined with DTIC in the treatment of malignant melanoma, 193
combined with DTIC and vincristine in the treatment of malignant melanoma, 205
combined with DTIC and vincristine in the treatment of metastatic cutaneous malignant melanoma, 1381
combined with 5-FU, DTIC, and vincristine in the treatment of advanced colorectal cancer, 29
combined with procarbazine in the treatment of malignant brain tumors, 243
combined with vincristine and DTIC, review of activity in malignant melanoma, 1141
effects on transcription in Ehrlich cells compared with cyclophosphamide and mechlorethamine, 471
intracarotid toxicity study of, in rhesus monkeys, 541
liposomal activation of, against Ehrlich ascites tumor and L1210 leukemia, 617
in malignant lymphomas, 739
phase II study of, combined with DTIC and hydroxyurea with or without vincristine in the treatment of disseminated melanomas, 189
phase II study of, combined with DTIC and vincristine with or without chlorpromazine in the treatment of disseminated melanomas, 189
proliferation character and growth modes of neoplastic disease in animals as determinants of chemotherapeutic efficacy, 1761
pulmonary toxicity in long-term administration of, 1691
size dependence of the response of Lewis lung tumors to, 1743
studies with 2,5-piperazinedione, 3,6-bis(5-chloro-2-piperidyl)-, dihydrochloride; biochemical and therapeutic effects in L1210 leukemias sensitive and resistant to alkylating agents: comparison with melphalan and cyclophosphamide, 1325
in the treatment of advanced Hodgkin's disease: remission induction and maintenance, 761
use in the LSA tumor model to study the growth characteristics of tumor cells by analysis of DNA distribution, 579
plus vincristine versus DTIC alone in the treatment of metastatic malignant melanoma, 595
1,2-Bis diazoacetyl ethane, antitumor activity of, in animals, 1601
Bladder cancer *see* Cancer, bladder
Bleomycin (NSC-125066)
alone followed by a combination of cyclophosphamide, vincristine, methotrexate, and 5-FU in the treatment of non-oat cell lung cancer, 61
as a cause of soft tissue metastatic calcification after treatment for lymphoma, 963
combined with adriamycin and vinblastine for advanced testicular tumors, 953
combined with adriamycin, vinblastine, and DTIC (ABVD) in the treatment of Hodgkin's disease, 205
combined with CCNU and vincristine in the treatment of stage III melanoma, 1273
combined with vinblastine and *cis*-dichlorodiammine-platinum(II) in the treatment of various cancers, phase I study, 91
dose fractionation does not prevent repair of potentially lethal damage induced by, in vivo, 259

Limulus amebocyte lysate assay used to detect the presence of bacterial endotoxin in various lots of, 9
recovery of mammalian cells in culture from induced, potentially lethal damage, 1791
used sequentially with cyclophosphamide, vincristine, methotrexate, adriamycin, and methyl-CCNU in the treatment of advanced, recurrent, squamous cancer of the head and neck, 103
plus vincristine and adriamycin compared to ICRF-159 alone in non-small cell lung cancer, 947
plus vincristine and adriamycin compared to VP-16-213 alone and vincristine plus cyclophosphamide and methotrexate in advanced small cell lung cancer, 949
B16 melanoma *see* Tumor systems in animals
Brain cancer *see* Cancer, brain
Breast cancer *see* Cancer, breast
Bronchogenic carcinoma *see* Cancer, lung
Bruceantin (NSC-165563)
a new plant-derived tumor inhibitor; mechanism of action, 1115
pharmacology of, 1127
Butocin (NSC-172755), results of testing against tumors in animals, 215

C

Calusterone (NSC-88536), in advanced breast cancer, 220
CAMP (cyclophosphamide, adriamycin, methotrexate, and procarbazine), for metastatic non-oat cell lung carcinoma, 1225
Camptothecin (NSC-100880), pharmacology of, 1127
Cancer (nonhematologic)
bladder, advanced, *cis*-dichlorodiammineplatinum(II) in, 917
brain
clinical studies with the nitrosoureas, 713
development of acute nonlymphocytic leukemia associated with previous nitrosourea therapy in 2 patients with, 1257
malignant, BCNU combined with procarbazine in the treatment of, 243
nitrosoureas in the treatment of, 719
role of surgery in, 717
breast
adrenalectomy and oophorectomy plus limited-term chemotherapy (cyclophosphamide, vincristine, methotrexate, and 5-FU) in the treatment of, 857
advanced, adriamycin and CCNU in the treatment of, 1687
advanced, comparison of tamoxifen and conventional hormone therapy (diethylstilbestrol) in patients with, 1461
advanced, evaluation of tamoxifen dose in, 1451
advanced, overview of EORTC clinical trials with tamoxifen in patients with, 1463
advanced, phase II evaluation of VP-16-213 and cytembena in, 953
advanced, phase II study of 5-FU combined with methotrexate, vincristine, cyclophosphamide, and prednisone in the treatment of: 2 years' followup, 107
advanced, phase II trial of cytembena in, 1655
advanced, therapeutic use of tamoxifen in: correlation with biochemical parameters, 1437
disseminated, 5-FU, cyclophosphamide, vincristine, and methotrexate, followed by citrovorum factor in the treatment of, combined with hormonal therapy, 85
evaluation of an intermittent schedule of dibromodulcitol in, 1593
interaction of antiestrogens with, in long-term tissue culture, 1421
isophosphamide in the treatment of, 955
metastatic, response to medroxyprogesterone acetate as secondary hormone therapy for, in postmenopausal women, 251
review of Cooper regimen in the treatment of, 1141
review of vincristine in the treatment of, 1141
role of radioautographic studies in clinical investigative oncology and chemotherapy in, 1873
stage IV, phase II study of tamoxifen in 74 patients with, 1431
stage IV, tamoxifen-induced remissions in, 1445
cervical, squamous cell, porfiromycin in the treatment of, 907
colon, hepatic artery infusion of 5-FUDR after prior systemic 5-FU in patients with, 1277
colorectal
advanced, 5-FU, BCNU, DTIC, and vincristine in the treatment of, 29
advanced, 5-FU, methyl-CCNU, and vincristine in: phase II study utilizing weekly 5-FU, 1597
advanced, methyl-CCNU in the treatment of, after 5-FU therapy, 235
metastatic, phase II study of ICRF-159 in patients with, previously exposed to systemic chemotherapy, 1395
phase II studies of dianhydrogalactitol and VP-16-213 in, 1247
staging, is there a role for liver biopsy?, 295
treated with methyl-CCNU and β-2'-deoxythioguanosine, 965
gastrointestinal
advanced, 5-FU alone compared to 5-FU and methyl-CCNU in the treatment of, 733
advanced, nitrosoureas in the treatment of, 769
advanced, phase II study using methyl-CCNU, 285
advanced, randomized comparison of melphalan and 5-FU in the treatment of, 1267
combination chemotherapy with mitomycin C, 5-FU, and cytosine arabinoside, 1373
hydrazine sulfate in, 933
nitrosoureas alone and in combination in the treatment of, 729
head and neck
randomized study of BACON versus BACON plus bacillus Calmette-Guérin in the treatment of, 535
squamous advanced recurrent, sequential combination chemotherapy for, 103
squamous cell, porfiromycin in the treatment of, 907
large intestine, adenocarcinoma, evaluation of daunorubicin in, 1667

lung
adenocarcinoma and large cell, methyl-CCNU, 5-FU, and vincristine in the treatment of, 1393
adenocarcinoma, phase II trial of 5-FU, adriamycin, and methotrexate in the treatment of, 623
advanced small cell, VP-16-213 versus polychemotherapy (vincristine plus cyclophosphamide and methotrexate; vincristine plus bleomycin and adriamycin) in, 949
CCNU combined with hexamethylmelamine and adriamycin in the treatment of, 269
chemotherapy for, with various drugs, 1479
combined surgery and chemotherapy for, 1489
cytologic diagnosis of, 1467
far-advanced, adriamycin in the treatment of, 939
general principles of surgical treatment of, 1473
heparin and cyclophosphamide in the treatment of, 575
histologic classification of, 1469
hydrazine sulfate in, 933
inoperable squamous and large cell, mechlorethamine plus CCNU in the treatment of, 625
isophosphamide in the treatment of, 955
metastatic non-oat cell, combination of cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP) in the effective treatment of, 1225
nitrosourea combinations in, 757
nitrosoureas as single agents in, 753
non-oat cell, bleomycin alone followed by cyclophosphamide, vincristine, methotrexate, and 5-FU in the treatment of, 61
non-small cell, ICRF-159 versus vincristine plus bleomycin and adriamycin in, 947
occurrence of, according to stage and determination of its dissemination, 1471
phase II evaluation of *cis*-dichlorodiammineplatinum(II) in, 1679
prerequisites for effective radiotherapy for, 1475
small cell anaplastic, vincristine in the treatment of, 239
small cell and adenocarcinoma, cyclophosphamide plus CCNU compared to cyclophosphamide alone in the treatment of, 925
small cell, conservative treatment of, 1483
small cell, phase II study of vinblastine, adriamycin, and procarbazine in the treatment of, 1263
squamous cell, porfiromycin in the treatment of, 907
undifferentiated, combination chemotherapy and radiotherapy for, 1487
lymphoreticular, summary of clinical results of phase II study in patients with, using the so-called synchronization therapy with vincristine and cyclophosphamide, 1959
oat cell, extensive, prolonged survival in patients treated with radiotherapy combined with methotrexate, vincristine, and cyclophosphamide, 221
ovarian
adenocarcinoma, advanced, phase II study of *cis*-dichlorodiammineplatinum(II) in, 55
advanced, phase II trial of cytembena in, 1655
epithelial, disseminated, phase I and II study of cytembena in the treatment of, 1389
isophosphamide in the treatment of, 955
methotrexate plus citrovorum factor rescue, alone and combined with cyclophosphamide, in the treatment of, 527
role of radioautographic studies in clinical investigative oncology and chemotherapy, 1873
pancreas, advanced phase II study of methyl-CCNU in, 1659
prostate, metastatic, adriamycin versus 5-FU and cyclophosphamide in the treatment of, 115
squamous cell, various sites, porfiromycin in the treatment of, 907
testicular, advanced, evaluation of bleomycin, adriamycin, and vinblastine in combination therapy for, 953
transitional cell, porfiromycin in the management of, a phase II study, 907

Carboxycyclophosphamide, qualitative and quantitative investigations by field-desorption mass spectrometry, 501

Carboxyphosphamide, permeation into animal tumor cells, 423

Carcinoid tumors, metastatic malignant, response to adriamycin, 273

Carcinoma *see* Cancer, type of

CCNU (NSC-79037)
and adriamycin in advanced breast cancer, 1687
in combination with DTIC and vincristine in the treatment of metastatic malignant melanoma, 601
combined with adriamycin and hexamethylmelamine in the treatment of lung cancer, 269
combined with mechlorethamine in the treatment of inoperable squamous and large cell carcinoma of the lung, 625
combined with vincristine and bleomycin in the treatment of stage III melanoma, 1273
plus cyclophosphamide compared to cyclophosphamide alone in the treatment of inoperable small cell carcinoma and adenocarcinoma of the lung, 925
in vitro response of mammalian cells to drug-induced potentially lethal and sublethal damage, 1799

Cell kinetics
age-dependent survival and cell-cycle progression of cultured cells exposed to chemotherapeutic drugs, 1707
arrested and cycling CHO cells as a kinetic model: studies with adriamycin, 1829
and cancer therapy: history, present status, and challenges, 1699
combined effects of cytosine arabinoside combined with either 6-thioguanine or 6-mercaptopurine; dose and time survival curves for leukemic colony-forming units and normal hematopoietic colony-forming units in mice, 1925
comparative chemosensitivity of exponential- versus plateau-phase cells in both in vitro and in vivo model systems, 1719
comparison of cell proliferation kinetics in human and experimental tumors: response to irradiation, 1887
computer simulation of leukemia therapy: combined pharmacokinetics, intracellular enzyme kinetics, and cell kinetics of the treatment of L1210 leukemia by cytosine arabinoside, 1723
cytotoxic damage and repair, 1777

effects of surgery on cell kinetics of residual tumors in animals, 1749
effects of tumor bearing on the dynamics of host hemopoietic cells, 1781
evidence for recruitment and synchronization in leukemia and solid tumors, 1841
investigation on pharmacologic induction of partial synchronization of tumor cell proliferation: its relevance for cytostatic therapy, 1959
in vitro responses of mammalian cells to drug-induced potentially lethal and sublethal damage, 1799
kinetic aids to proper chemotherapeutic scheduling: labeled nucleoside incorporation studies in vivo, 1947
kinetic response of human leukemic and lymphoma cells in vivo to combination chemotherapy using flow microfluorometry, 1937
mathematic models of cell synchrony and drug scheduling, 1899
physical-chemical characterization of living cells by laser-flow microfluorometry, 1819
proliferative character and growth modes of neoplastic disease as determinants of chemotherapeutic efficacy, using cyclophosphamide, BCNU, and adriamycin, 1761
rapid methods for utilizing cell kinetics for treatment in the C3H/He spontaneous mammary tumor: effects of vincristine, 1913
recovery of cells from induced, potentially lethal damage, 1791
resting cells in L1210 and JB-1 ascites tumors with special emphasis on recycling, 1861
role of radioautographic studies in clinical investigative oncology and chemotherapy, 1873
size dependence of the response of Lewis lung tumors to BCNU, 1743
synchronization with phase-specific agents in leukemia and correlation with clinical response, 1845
use of cell-cycle information in the preparation of drug combinations: results with cytosine arabinoside plus actinomycin D, 1813
Central nervous system, nitrosourea pharmacodynamics in relation to the, 725
Cephalotaxus, source of homoharringtonine and related anticancer alkaloids, 1157
Cervical cancer *see* Cancer, cervical
C3H/He *see* Tumor systems in animals
Chinese hamster ovary (CHO) cells
arrested and cycling cells as a kinetic model: studies with adriamycin, 1829
in vitro response to drug-induced potentially lethal and sublethal damage, 1799
Chlorambucil (NSC-3088), aspects of the teratology of, compared to cyclophosphamide, 477
Chloroplatinic acid (NSC-4958), nephrotoxicity of, in animals, 1675
Chlorozotocin, pharmacology of, 801
Chlorpromazine, combined with DTIC, BCNU, and vincristine versus the 3 drugs alone in the treatment of disseminated melanoma, 189
C3H mammary carcinoma *see* Tumor systems in animals
Chondrosarcoma *see* Tumor systems in animals
Chromomycin A_3 (NSC-58514), phase I alternate-day dose study of, 1251
CI-628, interaction with human breast cancer in long-term tissue culture, 1421
Cinerubin A (NSC-18334), activity of, against an adriamycin-resistant subline of P388 leukemia, 99
Citrovorum factor (NSC-3590)
plus 5-FU, cyclophosphamide, vincristine, and methotrexate and combined with hormonal therapy in the treatment of disseminated breast carcinoma, 85
plus methotrexate alone or with cyclophosphamide in the treatment of ovarian carcinoma, 527
preliminary studies of toxicity and responsiveness of Sarcoma 180 to DDMP combined with, 547
Clomiphene citrate, interaction with human breast cancer in long-term tissue culture, 1421
Coenzyme Q_{10} (NSC-140865), used to prevent the inhibition by adriamycin of coenzyme Q_{10} enzymes, 223
Colon cancer *see* Cancer, colon
Colorectal cancer *see* Cancer, colorectal (*see also* other individual sites)
Corynebacterium parvum, alone and in combination with adriamycin in experimental tumor systems, 823
Cyclocytidine (NSC-145668)
cardiovascular effects of, 1663
effects on ultrastructure of submaxillary salivary glands from mice treated with, compared to effects of cytosine arabinoside and anhydro-ara-5-fluorocytidine, 881
myelotoxicity and orthostatic hypotension of, 215
phase I–II study of, combined with DTIC in disseminated malignant melanoma, 1369
Cyclophosphamide (NSC-26271)
alone compared to cyclophosphamide and CCNU in the treatment of inoperable small cell carcinoma and adenocarcinoma of the lung, 925
approaches to the pharmacokinetics of, quantitation of metabolites, 403
aspects of the teratology of, compared to chlorambucil, 477
biologic activity in vitro of 2 derivatives and 6 possible metabolites of, 373
characterization of metabolites and related derivatives of, by field-desorption and electron-impact mass spectrometry, 509
combined with actinomycin D and vincristine in the treatment of advanced sarcomas: a comparative clinical trial with other single-agent and combination therapy, 1385
combined with adriamycin, methotrexate, and procarbazine (CAMP) in the effective treatment of metastatic non-oat cell lung carcinoma, 1225
combined with citrovorum factor rescue and methotrexate in the treatment of ovarian cancer, 527
combined with 5-FU versus adriamycin alone in the treatment of metastatic prostate cancer, 115
combined with heparin in the treatment of lung cancer, 575
combined with radiotherapy for undifferentiated lung cancer, 1487
combined with radiotherapy, vincristine, and metho-

trexate in the treatment of extensive oat cell carcinoma, 221
combined with surgery for lung cancer, 1489
combined with vincristine and methotrexate in the treatment of soft tissue sarcomas, 205
combined with vincristine, methotrexate, and 5-FU following bleomycin alone in the treatment of non-oat cell lung cancer, 61
combined with vincristine, summary of clinical results of phase II study in patients with lymphoreticular tumors by the so-called synchronization therapy, 1959
comparative pharmacologic study in vitro and in vivo with, and its metabolites and plain nitrogen mustard compounds, 301
disposition of, in tumor-bearing mice by means of gas chromatography-chemical ionization-mass fragmentography, 493
effects of, alone or combined with vincristine and prednisone on some hepatic oxidations and conjugations, 1285
effects of, in the treatment of metastatic prostate adenocarcinoma in germfree rats, 619
effects on transcription in Ehrlich cells compared with mechlorethamine and BCNU, 471
plus 5-FU, vincristine, and methotrexate and combined with adrenalectomy and oophorectomy in patients with breast cancer, 857
plus 5-FU, vincristine, methotrexate, and citrovorum factor and combined with hormonal therapy in the treatment of disseminated breast cancer, 85
importance of pharmacokinetic studies on, in understanding its cytotoxic effect, 395
Limulus amebocyte lysate assay used to detect the presence of bacterial endotoxin in various lots of, 9
metabolites, deactivation of, by sulfhydryl compounds, 355
metabolites, identification and pharmacokinetics of, in vivo, 415
permeation of metabolites of, into animal tumor cells, 423
phase II study with, combined with 5-FU, methotrexate, vincristine, and prednisone in the treatment of advanced breast cancer: 2 years' followup, 107
phase II trials, combined with adriamycin in the treatment of various solid tumors, 77
pretreatment, sparing effect of, on animals lethally treated with γ-irradiation, 409
problem of oncostatic specificity of: studies on reactions that control the alkylating and cytotoxic activity, 309
proliferative character and growth modes of neoplastic disease in animals as determinants of chemotherapeutic efficacy, 1761
qualitative and quantitative investigations of cyclophosphamide, cyclophosphamide metabolites, and related compounds by field-desorption mass spectrometry, 501
related phosphoramide mustards—recent advances and historical perspective, 337
some studies on the distribution and effects of, in normal and neoplastic tissues, 459
2 stable Fenton oxidation products of, as precursors of 4-hydroxycyclophosphamide under physiologic conditions, 369
studies on 4-hydroperoxycyclophosphamide: a simple preparation method and its application for the synthesis of a new class of "activated" sulfur-containing derivatives of, 429
studies on the enhancement of artificial lung metastasis after labeled cell inoculation, 465
studies on the in vivo formation of acrolein: 3-hydroxypropylmercapturic acid as an index of activation of, 327
studies on the selective action of: inactivation of the hydroxylated metabolite by tissue-soluble enzymes, 321
studies with 2,5-piperazinedione, 3,6-bis(5-chloro-2-piperidyl)-, dihydrochloride; biochemical and therapeutic effects in L1210 leukemias sensitive and resistant to alkylating agents: comparison with BCNU and melphalan, 1325
synthesis and structure-activity relationships of preactivated analogs of, tested against L1210 leukemia, 381
used sequentially with vincristine, bleomycin, methotrexate, adriamycin, and methyl-CCNU, in the treatment of advanced recurrent squamous cancer of the head and neck, 103
use of deuterated analogs in qualitative and quantitative investigations of the metabolism of, 483
plus vincristine and methotrexate compared to VP-16-213 alone and vincristine plus bleomycin and adriamycin in advanced small cell lung cancer, 949
X-ray crystallographic studies of derivatives of, 517
Cytembena (NSC-104801)
phase II evaluation of, with VP-16-213 in advanced breast cancer, 633
phase I and II study of, in disseminated epithelial ovarian cancers and sarcomas, 1389
phase II trial of, in advanced ovarian or breast cancer, 1655
Cytosine arabinoside (NSC-63878)
combined with actinomycin D: use of cell-cycle information in the preparation of drug combinations, 1813
combined with daunorubicin, 6-thioguanine, and pyrimethamine and compared to daunorubicin alone in the treatment of acute nonlymphocytic leukemia, 41
combined with 5-FU and mitomycin C in P815 ascites and solid mouse neoplasms, 1399
combined with 5-FU and mitomycin C in the treatment of gastrointestinal cancer, 1373
combined with 5-FU, 6-thioguanine, 6-mercaptopurine, 6-methylmercaptopurine riboside, and methotrexate, development of resistance to, in mice with L1210 leukemia, 23
combined with 6-mercaptopurine or 6-thioguanine; dose and time survival curves for leukemic colony-forming units and normal hematopoietic colony-forming units in mice, 1925
combined with vinblastine and procarbazine for reinduction of childhood acute myelocytic leukemia, 1683
compared to anhydro-ara-5-fluorocytidine in the treatment of murine brain tumor, 875
computer simulation of leukemia therapy: combined

pharmacokinetics, intracellular enzyme kinetics, and cell kinetics of the treatment of L1210 leukemia by, 1723
effects on ultrastructure of submaxillary salivary glands from mice treated with, compared to effects of cyclocytidine and anhydro-ara-5-fluorocytidine, 881
Limulus amebocyte lysate assay used to detect the presence of bacterial endotoxin in various lots of, 9
maintenance of remission in adult acute nonlymphocytic leukemia using intermittent courses of, with 6-thioguanine, 585
in sequence with daunorubicin in the treatment of acute myelogenous leukemia, 629
synchronization with, in patients with leukemia and correlation with clinical response, 1845
used to synchronize leukemic cells followed by vincristine, prednisone, and L-asparaginase for remission induction in advanced acute leukemia in children, 591

D

Daunorubicin (NSC-82151)
alone or combined with cytosine arabinoside, 6-thioguanine, and pyrimethamine in the treatment of acute nonlymphocytic leukemia, 41
evaluation of, in adenocarcinoma of the large intestine, 1667
Limulus amebocyte lysate assay used to detect the presence of bacterial endotoxin in various lots of, 9
in sequence with cytosine arabinoside in the treatment of acute myelogenous leukemia, 629
DDMP (pyrimidine, 2,4-diamino-5-(3,4-dichlorophenyl)-6-methyl-; NSC-19494), preliminary studies of toxicity and responsiveness of Sarcoma 180, used alone and combined with citrovorum factor, 547
3-Deazauridine (NSC-126849), synergistic interaction of, with D-galactosamine: enzyme pattern-directed chemotherapy, 835
4-Demethoxydaunorubicin (NSC-256439), synthesis and antitumor activity of, and 4-demethoxy-7,9-diepidaunorubicin and their β anomers, 829
4-Demethoxy-7,9-diepidaunorubicin, synthesis and antitumor activity of, and 4-demethoxydaunorubicin and their β anomers, 829
β-2′-Deoxythioguanosine (NSC-71261), combined with methyl-CCNU for advanced solid tumors, 965
Dianhydrogalactitol (NSC-132313)
phase I evaluation of, 611
phase II study in colorectal cancer, 1247
phase II study of, versus VP-16-213 in metastatic malignant melanoma, 1681
phase I trial of, administered iv in a weekly schedule, 895
preclinical toxicologic evaluation of, in dogs and monkeys, 1585
Dibromodulcitol (NSC-104800), evaluation of an intermittent schedule of, in breast cancer, 1593
***cis*-Dichlorodiammineplatinum(II) (NSC-119875)**
in advanced bladder cancer, 917
combined individually with 11 other drugs in vitro in a search for synergistic pairs, 1619
combined with bleomycin and vinblastine in the treatment of various cancers, phase I study, 91
nephrotoxicity of, in animals, 1675
phase II evaluation of, in lung cancer, 1679
phase II study of, in patients with advanced adenocarcinoma of the ovary, 55
Diethylstilbestrol (NSC-3070), compared with tamoxifen in advanced breast cancer, 1461
Dihydro-5-azacytidine hydrochloride (NSC-264880), a biologically active and chemically stable analog of 5-azacytidine, 1671
Dihydrofolate reductase, comparison of 4 antifolates as inhibitors of, 615
DON cells (Chinese hamster fibroblast line), in culture, use of cell-cycle information in the preparation of drug combinations: results with cytosine arabinoside plus actinomycin D, 1813
DTIC (NSC-45388)
alone or combined with methyl-CCNU or BCNU in the treatment of malignant melanoma, 193
alone or combined with adriamycin in the treatment of various sarcomas, 199
antitumor activity of, in animals, 135
clinical studies with, in various malignancies, 213
combined with adriamycin and vincristine in the treatment of advanced sarcomas: a comparative clinical trial with other single-agent and combination therapy, 1385
combined with adriamycin, bleomycin, and vinblastine (ABVD) in the treatment of Hodgkin's disease, 205
combined with adriamycin in the treatment of soft tissue sarcomas, 205
combined with bacillus Calmette-Guérin immunotherapy in the treatment of malignant melanoma, 177
combined with BCNU and actinomycin D in the treatment of malignant melanoma, 205
combined with BCNU and vincristine in the treatment of malignant melanoma, 205
combined with BCNU and vincristine in the treatment of metastatic cutaneous malignant melanoma, 1381
combined with 5-FU, BCNU, and vincristine in the treatment of advanced colorectal cancer, 29
combined with vincristine and BCNU, review of activity in malignant melanoma, 1141
combined with vincristine and BCNU, vincristine and hydroxyurea, and actinomycin D and BCNU in the treatment of advanced malignant melanoma, 33
experimental studies at Southern Research Institute with, 125
history and development of, 123
Limulus amebocyte lysate assay used to detect the presence of bacterial endotoxin in various lots of, 9
mechanism of action and pharmacology studies with, 149
phase I evaluation of, in the treatment of malignant melanoma, 183
phase I–II study of, combined with cyclocytidine in disseminated malignant melanoma, 1369
phase II study, combined with BCNU and hydroxyurea

with or without vincristine in the treatment of disseminated melanoma, 189
phase I study with, 189
phase II study in the treatment of Hodgkin's disease and other lymphomas, 189
phase II study of, combined with vincristine and BCNU with or without chlorpromazine in the treatment of disseminated melanomas, 189
randomized prospective trial of, alone versus BCNU plus vincristine in the treatment of metastatic malignant melanoma, 595
a review of its use in malignant melanoma, 165
studies on the mechanism of action of, 141
toxicity of, in man, 219
used alone and in various combinations with BCNU, CCNU, vincristine, and hydroxyurea in the treatment of metastatic malignant melanoma, 601

E

EARAD-1 leukemia *see* Tumor systems in animals
Echocardiography, evaluation of adriamycin cardiotoxicity in children, 1281
Ehrlich ascites tumor cells, inhibitors of hypoxanthine metabolism in, in vitro, 1567
Ehrlich carcinoma *see* Tumor systems in animals
Elephantin, a new plant-derived tumor inhibitor, mechanism of action, 1115
Elephantopin and derivatives, a new plant-derived tumor inhibitor, mechanism of action, 1115
Endotoxin, *Limulus amebocyte* lysate assay to detect the presence of, in chemotherapeutic agents, 9

F

Fluorescence scanner, thin-film, rapid analytic method for adriamycin and metabolites in human plasma, 1611
5-Fluorouracil (NSC-19893; 5-FU)
alone and compared to 5-FU and methyl-CCNU in advanced gastrointestinal cancer, 733
combined with cyclophosphamide versus adriamycin alone in the treatment of metastatic prostate cancer, 115
combined with cyclophosphamide, vincristine, and methotrexate following bleomycin alone in the treatment of non-oat cell lung cancer, 61
combined with DTIC, BCNU, and vincristine in the treatment of advanced colorectal cancer, 29
combined with 6-mercaptopurine, 6-thioguanine, 6-methylmercaptopurine riboside, cytosine arabinoside, and methotrexate, development of resistance to, in mice with L1210 leukemia, 23
combined with methyl-CCNU and vincristine in the treatment of adenocarcinoma and large cell carcinoma of the lung, 1393
combined with mitomycin C and cytosine arabinoside in P815 ascites and solid mouse neoplasms, 1399
combined with mitomycin C and cytosine arabinoside in the treatment of gastrointestinal cancer, 1373
combined with radiotherapy for undifferentiated lung cancer, 1487
compared to ftorafur; quantitative and qualitative differences in toxicity to mice, 1335
compared to ftorafur; therapeutic response and development of resistance in murine tumors, 1347
plus cyclophosphamide, vincristine, methotrexate, and citrovorum factor and combined with hormonal therapy in the treatment of disseminated breast cancer, 85
dissociation of uptake of, from intracellular pH in Walker 256 carcinosarcoma, 867
failure of, in the treatment of advanced colorectal carcinoma, followed by methyl-CCNU, 235
plus 5-FU, vincristine, and methotrexate and combined with adrenalectomy and oophorectomy in patients with breast cancer, 857
hepatic artery infusion of 5-FUDR after prior systemic treatment with, 1277
neurotoxicity from administration of, reproduced by mitomycin C, 293
phase II study with, combined with methotrexate, vincristine, cyclophosphamide, and prednisone in the treatment of advanced breast cancer: 2 years' followup, 107
phase II trial of, combined with adriamycin and methotrexate in the treatment of lung adenocarcinoma, 623
physiologic disposition of, compared to 5-FUDR in mice bearing solid L1210 lymphocytic leukemia, 845
serpentine supravenous hyperpigmentation, 639
randomized comparison with melphalan in the treatment of advanced gastrointestinal cancer, 1267
use of, in an elemental diet in animals during treatment with, 17
weekly, combined with methyl-CCNU and vincristine in advanced colorectal carcinoma, 159
Flow microfluorometry
abstracts from Workshop on Flow Microfluorometry, part of Proceedings of the Symposium on Cell Kinetics and Cancer Chemotherapy, 1981
kinetic response of human leukemic and lymphoma cells in vivo to combination chemotherapy using, 1937
laser, physical-chemical characterization of living cells by, 1819
Ftorafur (NSC-148958)
compared to 5-FU; quantitative and qualitative differences in toxicity to mice, 1335
compared to 5-FU; therapeutic response and development of resistance in murine tumors, 1347
5-FUDR (NSC-83097)
hepatic artery infusion of, after prior systemic 5-FU, 1277
physiologic disposition of, compared to 5-FU in mice bearing solid L1210 lymphocytic leukemia, 845

G

D-Galactosamine, synergistic interaction with 3-deazauridine: enzyme pattern-directed chemotherapy, 835

Gardner 6C3HED lymphosarcoma *see* Tumor systems in animals
Gastrointestinal cancer *see* Cancer, gastrointestinal (*see also* other individual sites)
Glioma, malignant *see* Cancer, brain
Glioma 261 *see* Tumor systems in animals
Gross leukemia *see* Tumor systems in animals
Guérin carcinoma *see* Tumor systems in animals

H

Harding-Passey melanoma *see* Tumor systems in animals
Head and neck cancer *see* Cancer, head and neck
Hemopoietic cells, effects of tumor bearing on the dynamics of, in animals, 1781
Heparin, combined with cyclophosphamide in the treatment of lung cancer, 575
Hepatic artery infusion, of 5-FUDR after prior systemic 5-FU, 1277
Hepatoma 72 *see* Tumor systems in animals
Hexamethylmelamine (NSC-13875), combined with CCNU and adriamycin in the treatment of lung cancer, 269
Hodgkin's disease
advanced, BCNU in the treatment of, remission induction and maintenance, 761
advanced, 8-drug combination chemotherapy (MOPP alternating with ABDV) and local radiotherapy in the treatment of, 1217
hydrazine sulfate in, 933
mechlorethamine, vincristine, prednisone, and procarbazine (MOPP) versus adriamycin, bleomycin, vinblastine, and DTIC (ABVD) in the treatment of, 205
nitrosoureas in, 781
phase II study of DTIC in the treatment of, 189
review of vinblastine and vincristine in the treatment of, 1141
sequential laparoscopy and laparotomy combined with bone marrow biopsy in staging, 1231
Homoharringtonine, and related *Cephalotaxus* alkaloids, antitumor activity, isolation, structural characterization, synthesis, biogenesis, and mechanism of action of, 1157
Hormones, therapy with, combined with combination chemotherapy in disseminated breast carcinoma, 85
Human epidermoid No. 2 tumor
comparison of cytotoxic and DNA synthesis inhibitory effects of 2,5-piperazinedione, 3,6-bis(5-chloro-2-piperidyl)-, dihydrochloride and 2,5-piperazinedione, 3,6-bis(1-azabicyclo[3.1.0]hex-2-yl)- in, 1317
studies with 2,5-piperazinedione, 3,6-bis(5-chloro-2-piperidyl)-, dihydrochloride: kinetic and biologic effects in cultured cells, 1307
Hydrazine sulfate (NSC-150014)
clinical data on the activity of, 933
clinical trial of, in solid tumors, 959
in the treatment of cancer, 964
4-Hydroperoxycyclophosphamide (NSC-181815)
biologic activity in vitro compared to other derivatives and possible metabolites of cyclophosphamide, 373
cytostatic and chemical properties of, compared to 4-hydroxycyclophosphamide, 369
permeation into animal tumor cells, 423
studies on, a simple preparation method and its application for the synthesis of a new class of "activated" sulfur-containing cyclophosphamide derivatives, 429
X-ray crystallographic studies of, 517
4-Hydroperoxyisophosphamide (NSC-227114)
stereochemistry, metabolism, and antitumor activity of, and its stereoisomer, 361
X-ray crystallographic studies of stereoisomers of, 517
4-Hydroxycyclophosphamide (NSC-196562)
anhydro-dimer, biologic activity in vitro compared to other derivatives and possible metabolites of cyclophosphamide, 373
anhydro-dimer, cytostatic and chemical properties of, compared to 4-hydroxycyclophosphamide, 369
characterization of, by field-desorption and electron-impact mass spectrometry, 509
deactivation of, by sulfhydryl compounds, 355
pharmacokinetics of, in vivo, 415
qualitative and quantitative investigations by field-desorption mass spectrometry, 501
synthesis and activity of in vitro, 429
3-Hydroxypropylmercapturic acid, as an index of cyclophosphamide activation, studies on the in vivo formation of acrolein, 327
Hydroxylamine mustard, biologic activity in vitro compared to other derivatives and possible metabolites of cyclophosphamide, 373
Hydroxyurea (NSC-32065)
combined with DTIC and vincristine in the treatment of advanced malignant melanoma, 33
combined with DTIC plus BCNU in the treatment of metastatic malignant melanoma, 601
phase II study, combined with BCNU and DTIC with or without vincristine in the treatment of disseminated melanomas, 189
synchronization with, in patients with leukemia and correlation with clinical responses, 1845
used sequentially with vincristine to enhance the degree of cell synchrony in animal tumors, 1959
use in the LSA tumor model to study the growth characteristics of tumor cells by analysis of DNA distribution, 579
Hyperthermia, used sequentially with irradiation, recovery of mammalian cells in culture from induced potentially lethal damage, 1791
Hypoxanthine metabolism, inhibitors of, in Ehrlich ascites tumor cells in vitro, 1567

I

ICRF-159 (NSC-129943)
phase II study of, in patients with metastatic colorectal carcinoma previously exposed to systemic chemotherapy, 1395
in the treatment of Kaposi's sarcoma, 111
versus vincristine plus bleomycin and adriamycin in non-small cell lung cancer, 947

Immunotherapy *see* Bacillus Calmette-Guérin and *Corynebacterium parvum*
Inosine dialdehyde (NSC-118994)
pharmacologic disposition of, in mice, rats, dogs, and monkeys, 555
protein cross-linking properties of, 563
Isophosphamide (NSC-109724)
biologic activity in vitro compared to other derivatives and possible metabolites of cyclophosphamide, 373
further experience with, in man, 955
studies on the clinical pharmacology and toxicology of, 445
studies on the human pharmacokinetics of, 451
studies on the metabolism of, in man, 437
synthesis and structure-activity relationships of preactivated analogs of, tested against L1210 leukemia, 381

J

Jatrophone, a new plant-derived tumor inhibitor; mechanism of action, 1115
JB-1 ascites tumor *see* Tumor systems in animals

K

Kaposi's sarcoma *see* Sarcoma, Kaposi's
4-Ketocyclophosphamide, biologic activity in vitro compared to other derivatives and possible metabolites of cyclophosphamide, 373

L

La leukemia *see* Tumor systems in animals
Lapachol (NSC-11905), pharmacology of, 1127
Laparoscopy, used sequentially with laparotomy combined with bone marrow biopsy in staging Hodgkin's disease, 1231
Laparotomy, used sequentially with laparoscopy combined with bone marrow biopsy in staging Hodgkin's disease, 1231
Large intestine cancer *see* Cancer, large intestine
Laser differential light-scattering bioassay, for methotrexate, 225
Leo-1031 (NSC-134087), study of, in the treatment of lymphocytic lymphoma and chronic lymphocytic leukemia, 277
Leukemia
acute
childhood, advanced, cytosine arabinoside synchronization of leukemic cells followed by vincristine, prednisone, and L-asparaginase for remission induction in, 591
childhood, late-stage, VM-26 in a phase I–II trial in the treatment of, 265
myelocytic, childhood, vinblastine, procarbazine, and cytosine arabinoside combined for reinduction of, 1683
myelogenous, sequencing of cytosine arabinoside and daunorubicin in, 629
nonlymphocytic
in adults, maintenance of remission, using intermittent courses of cytosine arabinoside and 6-thioguanine, 585
L-asparaginase activity in, 966
daunorubicin alone or combined with cytosine arabinoside, 6-thioguanine, and pyrimethamine in the treatment of, 41
developing in patients previously treated with nitrosoureas, 1257
symptomatic hypophosphatemia secondary to 5-azacytidine therapy of, 1400
role of radioautographic studies in clinical investigative oncology and chemotherapy in, 1873
VP-16-213 in the treatment of, 967
chronic lymphocytic, study of Leo-1031 in the treatment of, 277
evidence for recruitment and synchronization in, 1841
kinetic response of human cells in vivo to combination chemotherapy using flow microfluorometry, 1937
L1210 cells in culture, use of cell-cycle information in the preparation of drug combinations: results with cytosine arabinoside plus actinomycin D, 1813
synchronization with phase-specific agents in patients with, and correlation with clinical response, 1845
Levamisole (NSC-177023)
in clinical immunotherapy, 217
modulating effects of, on human lymphocyte response in vivo, 571
in a phase I trial, 963
Lewis lung carcinoma *see* Tumor systems in animals
Limulus amebocyte, used in an assay to detect the presence of bacterial endotoxin in chemotherapeutic agents, 9
Liposomal potentiation, of the antitumor activity of BCNU and mechlorethamine against Ehrlich ascites tumor and L1210 leukemia, 617
L1210 leukemia (*see also* Tumor systems in animals), amino acid-conferred resistance to melphalan: structure-activity relationship in cultured cells, 1363
LSA tumor model (a lymphoblastic lymphoma syngeneic for the C57BL mouse), growth characteristics of tumor cells by analysis of DNA distribution using mechlorethamine, BCNU, radiation, and hydroxyurea, 579
Lung cancer *see* Cancer, lung
L5178Y leukemia *see* Tumor systems in animals
Lymphocytes, in culture, modulating effects of levamisole on cell response, 571
Lymphoma
correlation of cell morphology, population kinetics, and clinical course as a guide to the study of new drugs and combinations, 1873
human cells in culture, age-dependent survival and cell-cycle progression of cells exposed to chemotherapeutic drugs, 1707
human cells in culture, *cis*-dichlorodiammineplat-

inum (II) combined individually with 11 other drugs in a search for synergistic pairs, 1619
human cells in culture, survival and cycle-progression delay of, with Yoshi 864, 1637
kinetic response of human cells in vivo to combination chemotherapy using flow microfluorometry, 1937
lymphocytic, study of Leo-1031 in the treatment of, 277
malignant, BCNU in the treatment of, 739
survival and cycle-progression delay of human cells in vitro exposed to VP-16-213, 1295
Lymphoreticular tumors *see* Cancer, lymphoreticular

M

Mass fragmentography, disposition of cyclophosphamide in tumor-bearing mice by means of gas chromatography-chemical ionization-mass fragmentography, 493
Mass spectrometry
characterization of cyclophosphamide derivatives and metabolites by field-desorption and electron-impact, 509
field-desorption, qualitative and quantitative investigations of cyclophosphamide, cyclophosphamide metabolites, and related compounds by, 501
Maytansine (NSC-153858)
pharmacology of, 1127
and related maytansinoids, new plant-derived tumor inhibitors; mechanism of action, 1115
Mechlorethamine (NSC-762)
combined with CCNU in the treatment of inoperable squamous and large cell carcinoma of the lung, 625
combined with prednisone, vincristine, and procarbazine (MOPP) in the treatment of Hodgkin's disease, 205
effects on transcription in Ehrlich cells compared with cyclophosphamide and BCNU, 471
liposomal activation of, against Ehrlich ascites tumor and L1210 leukemia, 617
recovery of mammalian cells in culture from induced potentially lethal damage, 1791
use in the LSA tumor model to study the growth characteristics of tumor cells by analysis of DNA distribution, 579
Medroxyprogesterone acetate (NSC-26386), response to, as secondary hormone therapy for metastatic breast cancer in postmenopausal women, 251
Melanoma
advanced malignant, comparative evaluation of DTIC, vincristine, and BCNU; DTIC, vincristine, and hydroxyurea; and DTIC, actinomycin D, and BCNU in the treatment of, 33
disseminated malignant, phase I–II study of DTIC and cyclocytidine in, 1369
disseminated, nitrosoureas in the management of, 747
disseminated, phase II study; DTIC, BCNU, and hydroxyurea with or without vincristine in the treatment of, 187
disseminated, phase II study of DTIC, BCNU, and vincristine with or without chlorpromazine in the treatment of, 189
malignant, bacillus Calmette-Guérin immunotherapy combined with DTIC in the treatment of, 177
malignant, DTIC alone and combined with methyl-CCNU or BCNU in the treatment of, 193
malignant, DTIC, BCNU, and either actinomycin D or vincristine in the treatment of, 205
malignant, natural history of, as related to therapy, 153
malignant, phase I evaluation of DTIC, 183
malignant, review of activity of DTIC, BCNU, and vincristine in, 1141
malignant, a review of the activity of "standard" and investigational agents in, 165
malignant, a review of DTIC in, 165
malignant, surgical treatment of, 159
metastatic cutaneous malignant, combination cytotoxic chemotherapy with DTIC, BCNU, and vincristine, 1381
metastatic malignant, phase II study of VP-16-213 versus dianhydrogalactitol, 1681
metastatic malignant, randomized prospective trial of DTIC alone versus BCNU plus vincristine in the treatment of, 595
metastatic malignant, DTIC alone and in various combinations with BCNU, CCNU, vincristine, and hydroxyurea in the treatment of, 601
role of radioautographic studies in clinical investigative oncology and chemotherapy in, 1873
stage III, combination of CCNU, vincristine, and bleomycin in the treatment of, 1273
Melphalan (NSC-8806)
amino acid-conferred resistance to; structure-activity relationship in cultured murine L1210 leukemia cells, 1363
randomized comparison with 5-FU in the treatment of advanced gastrointestinal cancer, 1267
studies with 2,5-piperazinedione, 3,6-bis(5-chloro-2-piperidyl), dihydrochloride; biochemical and therapeutic effects in L1210 leukemias sensitive and resistant to alkylating agents: comparison with BCNU and cyclophosphamide, 1325
6-Mercaptopurine (NSC-755)
combined with cytosine arabinoside; dose and time survival curves for leukemic colony-forming units and normal hematopoietic colony-forming units in mice, 1925
combined with 6-thioguanine, 6-methylmercaptopurine riboside, methotrexate, 5-FU, and cytosine arabinoside; development of resistance to, in mice with L1210 leukemia, 23
Methasquin (NSC-122870), competitive dihydrofolate reductase binding assay of, 615
Methotrexate (NSC-740)
plus citrovorum factor rescue alone or with cyclophosphamide in the treatment of ovarian carcinoma, 527
combined with cyclophosphamide, adriamycin, and procarbazine (CAMP) in the effective treatment of metastatic non-oat cell lung carcinoma, 1225
combined with cyclophosphamide and vincristine in the treatment of soft tissue sarcomas, 205
combined with cyclophosphamide, vincristine, and 5-FU following bleomycin alone in the treatment of non-oat cell lung cancer, 61

combined with 6-mercaptopurine, 6-methylmercaptopurine riboside, 5-FU, 6-thioguanine, and cytosine arabinoside; development of resistance to, in mice with L1210 leukemia, 23
combined with radiotherapy, cyclophosphamide, and vincristine in the treatment of extensive oat cell carcinoma, 221
compared to triazinate, methasquin, and aminopterin as inhibitors of dihydrofolate reductase, 615
device for constant sc infusion of; plasma results in mice, 889
plus 5-FU, cyclophosphamide, vincristine, and citrovorum factor and combined with hormonal therapy in the treatment of disseminated breast cancer, 85
inhibition of transport of, from cerebrospinal fluid by probenecid, 913
laser differential light-scattering bioassay for, 225
phase II study with, combined with 5-FU, vincristine, cyclophosphamide, and prednisone in the treatment of advanced breast cancer: 2 years' followup, 107
phase II trial of, combined with 5-FU and adriamycin in the treatment of lung adenocarcinoma, 623
synchronization with, in patients with leukemia and correlation with clinical responses, 1845
used sequentially with cyclophosphar..ide, vincristine, bleomycin, adriamycin, and methyl-CCNU in the treatment of advanced recurrent squamous cancer of the head and neck, 103
plus vincristine and cyclophosphamide compared to VP-16-213 alone and vincristine plus bleomycin and adriamycin in advanced small cell lung cancer, 949
plus vincristine, cyclophosphamide, and 5-FU and combined with adrenalectomy and oophorectomy in patients with breast cancer, 857
Methoxsalen (NSC-45923), bis-chloroethyl derivatives of, potential agents against malignant melanoma, 217
Methyl-CCNU (NSC-95441)
combined with β-2'-deoxythioguanosine for advanced solid tumors, 965
combined with DTIC in the treatment of malignant melanoma, 193
combined with 5-FU and compared to 5-FU alone in advanced gastrointestinal cancer, 733
combined with 5-FU and vincristine in the treatment of adenocarcinoma and large cell carcinoma of the lung, 1393
combined with vincristine and weekly 5-FU in advanced colorectal carcinoma, 1597
in vitro responses of mammalian cells to drug-induced potentially lethal and sublethal damage, 1799
phase II study of, in the treatment of advanced gastrointestinal cancer, 285
phase II study of, in the treatment of advanced pancreatic carcinoma, 1659
preclinical toxicologic evaluation of a single iv infusion in dogs and monkeys, 1559
in the treatment of advanced colorectal cancer after failure of 5-FU therapy, 235
in the treatment of advanced sarcomas: a comparative clinical trial with two 3-drug combinations, 1385
used sequentially with cyclophosphamide, vincristine, bleomycin, methotrexate, and adriamycin in the treatment of advanced, recurrent, squamous cancer of the head and neck, 103
6-Methylmercaptopurine riboside (NSC-40774), combined with 6-thioguanine, 6-mercaptopurine, methotrexate, 5-FU, and cytosine arabinoside; development of resistance to, in mice with L1210 leukemia, 23
Methylmethane sulfonate, recovery of mammalian cells in culture from induced potentially lethal damage, 1791
Mitomycin C (NSC-26980)
combined with 5-FU and cytosine arabinoside in P815 ascites and solid mouse neoplasms, 1399
combined with 5-FU and cytosine arabinoside in the treatment of gastrointestinal cancer, 1373
neurotoxicity from 5-FU administration reproduced by, 293
oral, phase I study of, 1633
MOPP (mechlorethamine, vincristine, prednisone, and procarbazine)
alternating with ABDV (adriamycin, bleomycin, DTIC, and vinblastine) in radiotherapy for advanced Hodgkin's disease, 1217
outline of original clinical study with, 1141
versus adriamycin, bleomycin, vinblastine, and DTIC (ABVD) in the treatment of Hodgkin's disease, 205
Myeloma, multiple, nitrosoureas in, 789

N

Nafoxidine, interaction with human breast cancer in long-term tissue culture, 1421
Nitrogen mustards (*see also* mechlorethamine), pharmacologic study in vitro and in vivo compared with cyclophosphamide and cyclophosphamide metabolites, 301
Nitrosoureas (*see also* specific agents)
chemistry and structure-activity studies of, 651
clinical studies in malignant gliomas, 713
clinical schedules and toxic effects, 709
clinical studies in various solid tumors, 795
combinations of, in lung cancer, 757
development of acute nonlymphocytic leukemia associated with previous therapy with, 1257
early history and development of, 647
future studies with, based on review of past studies, 807
in the management of disseminated malignant melanoma, 747
mechanism of action of, 699
in multiple myeloma, 789
pharmacodynamics of, in relation to the central nervous system, 725
pharmacology of, 703
review of experimental antitumor activity, 665
as single agents in the treatment of lung cancer, 753
therapy for gastrointestinal cancer, used alone and in combination, 729
in the treatment of advanced gastrointestinal cancer, 769
in the treatment of Hodgkin's disease, 781
in the treatment of primary malignant gliomas, 719
***Nor*-nitrogen mustard** (NSC-10873)
biologic activity in vitro compared to other derivatives and possible metabolites of cyclophosphamide, 373

permeation into animal tumor cells, 423
qualitative and quantitative investigations by field-desorption mass spectrometry, 501
NSC-739 *see* Aminopterin
NSC-740 *see* Methotrexate
NSC-752 *see* 6-Thioguanine
NSC-755 *see* 6-Mercaptopurine
NSC-762 *see* Mechlorethamine
NSC-3053 *see* Actinomycin D
NSC-3061 *see* Pyrimethamine
NSC-3070 *see* Diethylstilbestrol
NSC-3088 *see* Chlorambucil
NSC-3590 *see* Citrovorum factor
NSC-4958 *see* Chloroplatinic acid
NSC-6396 *see* ThioTEPA
NSC-8806 *see* Melphalan
NSC-10023 *see* Prednisone
NSC-10873 *see* *Nor*-nitrogen mustard
NSC-11905 *see* Lapachol
NSC-13875 *see* Hexamethylmelamine
NSC-18334 *see* Cinerubin A
NSC-18786 *see* Probenecid
NSC-19494 *see* DDMP [pyrimidine, 2,4-diamino-5-(3,4-dichlorophenyl)-6-methyl-]
NSC-19893 *see* 5-Fluorouracil
NSC-26271 *see* Cyclophosphamide
NSC-26386 *see* Medroxyprogesterone acetate
NSC-26980 *see* Mitomycin C
NSC-32065 *see* Hydroxyurea
NSC-40774 *see* 6-Methylmercaptopurine riboside
NSC-42076 *see* SPG-827
NSC-45388 *see* DTIC
NSC-45923 *see* Methoxsalen
NSC-49842 *see* Vinblastine
NSC-56410 *see* Porfiromycin
NSC-58514 *see* Chromomycin A_3
NSC-63878 *see* Cytosine arabinoside
NSC-67574 *see* Vincristine
NSC-68075 *see* Thalicarpine
NSC-69945 *see* Phosphoramide mustard
NSC-69947 *see* Phosphoramide mustards
NSC-71047 *see* Trioxsalen
NSC-71261 *see* β-2′-Deoxythioguanosine
NSC-72274 *see* SPI-77
NSC-72505 *see* Phosphoramide mustards
NSC-72510 *see* Phosphoramide mustards
NSC-77213 *see* Procarbazine
NSC-79037 *see* CCNU
NSC-82151 *see* Daunorubicin
NSC-82623 *see* Vitamin E
NSC-83097 *see* 5-FUDR
NSC-85998 *see* Streptozotocin
NSC-88536 *see* Calusterone
NSC-91523 *see* Propranolol
NSC-95441 *see* Methyl-CCNU
NSC-100880 *see* Camptothecin
NSC-102627 *see* Yoshi 864
NSC-102816 *see* 5-Azacytidine
NSC-104800 *see* Dibromodulcitol
NSC-104801 *see* Cytembena
NSC-109229 *see* L-Asparaginase
NSC-109723 *see* Trophosphamide
NSC-109724 *see* Isophosphamide
NSC-112907 *see* Tetrahydrouridine
NSC-118994 *see* Inosine dialdehyde
NSC-119875 *see* *cis*-Dichlorodiammineplatinum(II)
NSC-122819 *see* VM-26
NSC-122870 *see* Methasquin
NSC-123127 *see* Adriamycin
NSC-125066 *see* Bleomycin
NSC-126849 *see* 3-Deazauridine
NSC-129943 *see* ICRF-159
NSC-132313 *see* Dianhydrogalactitol
NSC-134087 *see* Leo-1031
NSC-135758 *see* 2,5-Piperazinedione, 3,6-bis(5-chloro-2-piperidyl)-, dihydrochloride
NSC-139105 *see* Triazinate
NSC-104865 *see* Coenzyme Q_{10}
NSC-141540 *see* VP-16-213
NSC-145668 *see* Cyclocytidine
NSC-148958 *see* Ftorafur
NSC-150014 *see* Hydrazine sulfate
NSC-153858 *see* Maytansine
NSC-165563 *see* Bruceantin
NSC-166641 *see* Anhydro-ara-5-fluorocytidine
NSC-172755 *see* Butocin
NSC-176986 *see* 4-Peroxycyclophosphamide
NSC-177023 *see* Levamisole
NSC-178248 *see* Chlorozotocin
NSC-180512 *see* Platinum uracil blue
NSC-180973 *see* Tamoxifen
NSC-181815 *see* 4-Hydroperoxycyclophosphamide
NSC-196562 *see* 4-Hydroxycyclophosphamide
NSC-201424 *see* 2,5-Piperazinedione, 3,6-bis(1-azabicyclo[3.1.0]hex-2-yl)-
NSC-224964 *see* Platinum, (1,2-cyclohexanediamine-*N*,*N*′)[propanedioato-(2-)-*O*,*O*′]-, (*SP*-4-2)-
NSC-227114 *see* 4-Hydroperoxyisophosphamide
NSC-239851 *see* Platinum, (1,2-cyclohexanediamine-*N*,*N*′)bis(nitrato-*O*)-, (*SP*-4-2)-
NSC-250427 *see* Platinum, (1,2-cyclohexanediamine-*N*,*N*′)[sulfato(2-)-*O*,*O*′]-, (*SP*-4-2)-
NSC-256439 *see* 4-Demethoxydaunorubicin
NSC-264880 *see* Dihydro-5-azacytidine hydrochloride
NSC-409962 *see* BCNU

O

Oat cell cancer *see* Cancer, oat cell
Oophorectomy *see* Surgery
Ovarian cancer *see* Cancer, ovarian

P

Pancreatic cancer *see* Cancer, pancreas
P388 leukemia *see* Tumor systems in animals
P815 ascites and solid mouse neoplasms *see* Tumor systems in animals
4-Peroxycyclophosphamide (NSC-176986), activity against L1210 leukemia, Lewis lung carcinoma, and C3H mammary tumor, 381

Phase I studies
alternate-day dose study of chromomycin A_3, 1251
of dianhydrogalactitol, 611
of dianhydrogalactitol administered iv in a weekly schedule, 895
of DTIC, 189
of DTIC in the treatment of malignant melanoma, 183
of levamisole, 963
of oral mitomycin C, 1633
of an oral solution of VP-16-213, 943
and phase II study of cytembena in disseminated epithelial ovarian cancers and sarcomas, 1389
and phase II study of DTIC and cyclocytidine in disseminated malignant melanoma, 1369
and phase II study of single-dose actinomycin D, pharmacokinetically based, 289
and phase II trial of VM-26 in the treatment of children with late-stage leukemia, 265
of vinblastine combined with bleomycin and *cis*-dichlorodiammineplatinum(II) in the treatment of various cancers, 91
of weekly administration of anhydro-ara-5-fluorocytidine, 281
Phase II studies
of *cis*-dichlorodiammineplatinum(II) in lung cancer, 1679
of *cis*-dichlorodiammineplatinum(II) in patients with advanced adenocarcinoma of the ovary, 55
of cyclophosphamide and adriamycin in the treatment of various solid tumors, 77
of cytembena in advanced ovarian or breast cancer, 1655
of dianhydrogalactitol and VP-16-213 in colorectal cancer, 1247
of DTIC combined with BCNU and hydroxyurea with or without vincristine in the treatment of disseminated melanomas, 189
of DTIC combined with vincristine and BCNU with or without chlorpromazine in the treatment of disseminated melanomas, 189
of DTIC in the treatment of Hodgkin's disease and other lymphomas, 189
of 5-FU, adriamycin, and methotrexate in the treatment of lung adenocarcinoma, 623
of 5-FU, methotrexate, vincristine, cyclophosphamide, and prednisone in the treatment of advanced breast cancer: 2 years' followup, 107
of ICRF-159 in patients with metastatic colorectal carcinoma previously exposed to systemic chemotherapy, 1395
of methyl-CCNU in advanced pancreatic carcinoma, 1659
of methyl-CCNU in the treatment of advanced gastrointestinal cancer, 285
and phase I study of cytembena in disseminated epithelial ovarian cancers and sarcomas, 1389
and phase I study of DTIC and cyclocytidine in disseminated malignant melanoma, 1369
and phase I study of single-dose actinomycin D, pharmacokinetically based, 289
and phase I trial of VM-26 in the treatment of children with late-stage leukemia, 265
of porfiromycin in the management of epidermoid and transitional cell cancer, 907
of tamoxifen: report of 74 patients with stage IV breast cancer, 1431
using methyl-CCNU, vincristine, and weekly 5-FU in advanced colorectal cancer, 1597
of vinblastine, adriamycin, and procarbazine in small cell carcinoma of the lung, 1263
vincristine combined with cyclophosphamide; summary of clinical results of a study in patients with lymphoreticular tumors by the so-called synchronization therapy, 1959
of VP-16-213 and cytembena in advanced breast cancer, 633
of VP-16-213 versus dianhydrogalactitol in metastatic malignant melanoma, 1681
Phenylalanine ammonia-lyase, in vivo effects of, in animals, 261
Phosphoramide mustard (NSC-69945)
characterization of, by field-desorption and electron-impact mass spectrometry, 509
derivatives of amino acids and peptides, 347
quantitation of, in human serum and urine using gas chromatography-chemical ionization-mass spectrometry, 403
synthesis and structure-activity relationships of preactivated analogs of, tested against L1210 leukemia, 381
Phosphoramide mustards, antitumor activity of NSC-69945 compared to other active phosphoramide mustards (NSC-69947, NSC-72505, and NSC-72510), 337
2,5-Piperazinedione, 3,6-bis(1-azabicyclo[3.1.0]hex-2-yl)-(NSC-201424), comparison with 2,5-piperazinedione, 3,6-bis(5-chloro-2-piperidyl)-, dihydrochloride: cytotoxic and DNA synthesis inhibitory studies in human epidermoid No. 2 cells, 1317
2,5-Piperazinedione, 3,6-bis(5-chloro-2-piperidyl)-, dihydrochloride (NSC-135758)
cell kinetic and biologic effects in cultured L1210, human epidermoid No. 2, and Adenocarcinoma 755 cells, 1307
effects on macromolecular synthesis in cell culture and evidence for alkylating activity, 1317
studies with; biochemical and therapeutic effects in L1210 leukemias sensitive and resistant to alkylating agents: comparison with melphalan, cyclophosphamide, and BCNU, 1325
Plant products
bioassay of extracts for antitumor activity, 1007
in clinical cancer chemotherapy, 1141
distribution of anticancer activity in, 1081
folklore, a tool for predicting sources of antitumor activity, 979
history of the National Cancer Institute's screening program for, 975
isolation and chemical characterization of antitumor agents from, 1011
novel plant-derived tumor inhibitors and their mechanisms of action, 1115
oncogenic and tumor-promoting spermatophytes and pteridophytes and their active principles, 1171
pharmacology of 9 antitumor agents from, 1127

preparation of extracts for antitumor screening, 999
procurement of, for antitumor screening, 987
as a source of anticancer drugs, 1069
types of anticancer agents isolated from, 1031
Platinum, (1,2-cyclohexanediamine-*N,N'*)bis(nitrato-*O*)-, (*SP*-4-2)-(NSC-239851), nephrotoxicity of, in animals, 1675
Platinum, (1,2-cyclohexanediamine-*N,N'*)[propanedioate-(2)-*O,O'*]-, (*SP*-4-2)- (NSC-224964), nephrotoxicity of, in animals, 1675
Platinum, (1,2-cyclohexanediamine-*N,N'*)[sulfato(2-)-*O,O'*]-, (*SP*-4-2)- (NSC-250427), nephrotoxicity of, in animals, 1675
Platinum uracil blue (NSC-180512), nephrotoxicity of, in animals, 1675
P388 leukemia *see* Tumor systems in animals
Podophyllotoxins (*see also* VP-16-213 and VM-26), compounds isolated from *Podophyllum* species, 1141
Porfiromycin (NSC-56410), in the management of epidermoid and transitional cell cancer: phase II study, 907
Prednisone (NSC-10023)
combined with mechlorethamine, vincristine, and procarbazine (MOPP) in the treatment of Hodgkin's disease, 205
combined with vincristine and L-asparaginase in a study of cytosine arabinoside synchronization of leukemic cells, for remission induction in advanced acute leukemia in children, 591
effects of, alone or combined with cyclophosphamide and vincristine on some hepatic oxidations and conjugations, 1285
phase II study with, combined with 5-FU, methotrexate, cyclophosphamide, and vincristine in the treatment of advanced breast cancer: 2 years' followup, 107
Probenecid (NSC-18786), inhibition of methotrexate transport from cerebrospinal fluid by, 913
Procarbazine (NSC-77213)
combined with adriamycin and vinblastine in a phase II study of small cell carcinoma of the lung, 1263
combined with BCNU in the treatment of malignant brain tumors, 243
combined with cyclophosphamide, adriamycin, and methotrexate (CAMP) in the effective treatment of metastatic non-oat cell lung carcinoma, 1225
combined with mechlorethamine, vincristine, and prednisone (MOPP) in the treatment of Hodgkin's disease, 205
combined with vinblastine and cytosine arabinoside for reinduction of childhood acute myelocytic leukemia, 1683
Propranolol (NSC-91523), bis-chloroethyl derivatives of, potential agents against lung cancer, 217
Prostatic cancer *see* Cancer, prostate
Pteridophytes, identification of oncogenic and tumor-promoting principles of, 1171
Purines, analogs and derivatives tested for ability to inhibit parameters of purine metabolism in Ehrlich ascites tumor cells, 1567
P815X2 mastocytoma *see* Tumor systems in animals
Pyrimethamine (NSC-3061), combined with daunorubicin, cytosine arabinoside, and 6-thioguanine and compared to daunorubicin alone in the treatment of acute nonlymphocytic leukemia, 41

R

Radiation therapy
combined with chemotherapy for small cell lung cancer, 1483
combined with cyclophosphamide, vincristine, and methotrexate in the treatment of extensive oat cell carcinoma, 221
combined with 8-drug chemotherapy (MOPP alternating with ABDV) in the treatment of advanced Hodgkin's disease, 1217
combined with 5-FU or cyclophosphamide for undifferentiated lung cancer, 1487
prerequisites for effective treatment of lung cancer, 1475
recovery of mammalian cells in culture from induced potentially lethal damage, 1791
response to, comparison of cell proliferation kinetics in human and experimental tumors, 1887
use in the LSA tumor model to study the growth characteristics of tumor cells by analysis of DNA distribution, 579
Rebuck skin window, as a guide in cancer chemotherapy, 903
Respiration, of tumor cells, effects and specificity of anticancer agents on, 1
Retinoids, inhibition of growth and regression of a transplantable rat chondrosarcoma by Ro 10–1670, Ro 10–9359, and Ro 11–1430, 1647

S

Saponin P, a new plant-derived tumor inhibitor; mechanism of action, 1115
Sarcoma
adriamycin and DTIC (used alone or as a combination) in the treatment of, 197
advanced, a comparative clinical trial evaluating the combination of adriamycin, DTIC, and vincristine, the combination of actinomycin D, cyclophosphamide, and vincristine, and methyl-CCNU alone in the treatment of, 1385
Kaposi's, ICRF-159 in the treatment of, 111
phase I and II study of cytembena in the treatment of, 1389
soft tissue, cyclophosphamide, vincristine, and methotrexate versus adriamycin and DTIC in the treatment of, 205
Sarcoma 45 *see* Tumor systems in animals
Sarcoma 180 *see* Tumor systems in animals
Schweitz erythromyelosis *see* Tumor systems in animals
Spermatophytes, identification of oncogenic and tumor-promoting principles of, 1171
SPG-827 (NSC-42076), review of clinical responses with, 1141
"Sphygmo-Recording," noninvasive monitoring of adria-

mycin cardiotoxicity by; technique to record the pulse wave delay (QK_{II} interval), 1239
SPI-77 (NSC-72274), review of activity and toxic effects in man, 1141
Squamous cell cancer *see* Cancer, squamous cell
Streptozotocin (NSC-85998), *Limulus amebocyte* lysate assay used to detect the presence of bacterial endotoxin in lots of, 9
Surgery
adrenalectomy and oophorectomy plus limited-term chemotherapy (cyclophosphamide, vincristine, methotrexate, and 5-FU) in the treatment of breast cancer, 857
combined with chemotherapy for lung cancer, 1489
effects of, on the cell kinetics of residual tumor in animals, 1749
general principles in the treatment of lung cancer, 1473
in the treatment of malignant gliomas, 717
treatment of malignant melanoma, 159

T

Tamoxifen (NSC-180973)
antiestrogenic and antitumor properties of, in laboratory animals, 1409
comparison with conventional hormone therapy (diethylstilbestrol) for advanced breast cancer, 1461
evaluation of dosage in advanced breast cancer, 1451
interaction of, with human breast cancer in long-term tissue culture, 1421
overview of EORTC clinical trials with, in patients with advanced breast cancer, 1463
phase II study of, in 74 patients with stage IV breast cancer, 1431
remissions in stage IV breast cancer, 1445
therapeutic use in advanced breast cancer: correlation with biochemical parameters, 1437
TA-3(St) tumor *see* Tumor systems in animals
Testicular cancer *see* Cancer, testicular
Tetrahydrouridine (NSC-112907), distribution of, in experimental animals, 1627
Thalicarpine (NSC-68075)
pharmacology of, 1127
plasma decay and excretion of, in man, 69
6-Thioguanine (NSC-752)
combined with cytosine arabinoside; dose and time survival curves for leukemic colony-forming units and normal hematopoietic colony-forming units in mice, 1925
combined with daunorubicin, cytosine arabinoside, and pyrimethamine and compared to daunorubicin alone in the treatment of acute nonlymphocytic leukemia, 41
combined with 6-mercaptopurine, methotrexate, 6-methylmercaptopurine riboside, 5-FU, and cytosine arabinoside; development of resistance to, in mice with L1210 leukemia, 23
maintenance of remission in adult acute nonlymphocytic leukemia using intermittent courses of, with cytosine arabinoside, 585
Thiopurines *see* 6-Mercaptopurine and 6-thioguanine
ThioTEPA (NSC-6396)
analogs, spin-labeled; toxicity, antitumor activity, and pharmacokinetics of, 1605
combined with surgery for lung cancer, 1489
α-Tocopherol *see* Vitamin E
Toxic reactions: observations in animals
cardiovascular effects of cyclocytidine, 1663
comparative nephrotoxicity of various platinum cancer chemotherapeutic agents, 1675
Toxic reactions: observations in man
amelioration of toxicity of adriamycin by α-tocopherol (vitamin E), 961
echocardiographic evaluation of adriamycin cardiotoxicity in children, 1281
neurotoxicity from 5-FU administration reproduced by mitomycin C, 293
noninvasive monitoring of adriamycin cardiotoxicity by "Sphygmo-Recording" of the pulse wave delay (QK_{II} interval), 1239
pigmentation of the tongue after treatment with adriamycin, 1402
pulmonary toxicity in long-term administration of BCNU, 1691
Rebuck skin window as a clinical test to evaluate risk for infection in neutropenic patients receiving chemotherapy, 903
serpentine supravenous 5-FU hyperpigmentation, 639
soft tissue metastatic calcification after bleomycin therapy for lymphoma, 963
studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity, 813
symptomatic hypophosphatemia secondary to 5-azacytidine therapy of acute nonlymphocytic leukemia, 1400
Transitional cell cancer *see* Cancer, transitional cell
Triazinate (NSC-139105), competitive dihydrofolate reductase binding assay of, 615
Triazine derivatives, effects and specificity of, on the respiration and energy metabolism of tumor cells, 1
Trioxsalen (NSC-71047), bis-chloroethyl derivatives of, potential agents against malignant melanoma, 217
Triptolides, new plant-derived tumor inhibitors, mechanism of action, 1115
Trophosphamide (also triphosphamide) (NSC-109723)
biologic activity in vitro compared to other derivatives and possible metabolites of cyclophosphamide, 373
synthesis and structure-activity relationships of preactivated analogs of, tested against L1210 leukemia, 381
X-ray crystallographic studies of, 517
Tumor systems in animals
Adenocarcinoma 755, antitumor activity of 1,2-bis diazoacetyl ethane in, 1601
B16 melanoma
antitumor activity of DTIC combined with adriamycin against, 135
comparison of activity of adriamycin and cinerubin A against, 99
comparison of 5-FU and ftorafur; therapeutic response and development of resistance in, 1347

comparison of phosphoramide mustards against, 337
effects of *Corynebacterium parvum* alone and in combination with adriamycin in, 823
in vivo effects of phenylalanine ammonia-lyase, 261
C3H/He spontaneous mammary tumor, rapid methods for utilizing cell kinetics for treatment in; effects of vincristine, 1913
C3H mammary carcinoma
antitumor activity of DTIC combined with adriamycin against, 135
comparison of activity of 4-peroxycyclophosphamide and cyclophosphamide against, 381
Chondrosarcoma, transplantable, inhibition of growth and regression of, by three retinoids, 1647
EARAD-1 leukemia, in vivo effects of phenylalanine ammonia-lyase, 261
Ehrlich carcinoma
ascites, effects of tumor bearing on the dynamics of host hemopoietic cells, 1781
ascites, investigations on kinetic data and reproducibility concerning the pharmacologic modification of cell proliferation after vincristine, 1959
liposomal activation of mechlorethamine and BCNU against, 617
Gardner 6C3HED lymphosarcoma, comparison of 5-FU and ftorafur; therapeutic response and development of resistance in, 1347
Glioma 261, comparison of anhydro-ara-5-fluorocytidine and cytosine arabinoside in the treatment of, 875
Gross leukemia, antitumor activity of 4-demethoxydaunorubicin, 4-demethoxy-7,9-diepidaunorubicin, and their β anomers in, 829
Guérin carcinoma
antitumor activity of 1,2-bis diazoacetyl ethane in, 1601
toxicity, antitumor activity, and pharmacokinetics of spin-labeled thioTEPA analogs, 1605
Harding-Passey melanoma, antitumor activity of 1,2-bis diazoacetyl ethane in, 1601
Hepatoma 72, antitumor activity of 1,2-bis diazoacetyl ethane in, 1601
JB-1 ascites tumor, resting cells in; with special emphasis on recycling, 1861
La leukemia, antitumor activity of 1,2-bis diazoacetyl ethane in, 1601
Lewis lung carcinoma
comparison of activity of adriamycin and cinerubin A against, 99
comparison of activity of 4-peroxycyclophosphamide and cyclophosphamide against, 381
comparison of phosphoramide mustards against, 337
disposition of cyclophosphamide in mice bearing, by gas chromatography-chemical ionization-mass fragmentography, 493
effects of *Corynebacterium parvum* alone and in combination with adriamycin, 823
effects of surgery on cell kinetics of residual tumors in, 1749
size dependence of the response of, to BCNU, 1743
L1210 leukemia
activity of some *Cephalotaxus* alkaloids against, 1157
antitumor activity of 1,2-bis diazoacetyl ethane in, 1601
antitumor activity of 4-demethoxydaunorubicin, 4-demethoxy-7,9-diepidaunorubicin, and their β anomers in, 829
antitumor activity of DTIC alone and combined with adriamycin against, 135
comparison of activity of adriamycin and cinerubin A against, 99
comparison of 5-FU and ftorafur; therapeutic response and development of resistance in, 1347
comparison of phosphoramide mustards against, 337
computer simulation of leukemia therapy: combined pharmacokinetics, intracellular enzyme kinetics, and cell kinetics of the treatment of, by cytosine arabinoside, 1723
development of resistance to combination of 6-mercaptopurine, 6-thioguanine, 6-methylmercaptopurine riboside, methotrexate, 5-FU, and cytosine arabinoside, 23
dose regimen studies with DTIC, 125
liposomal activation of mechlorethamine and BCNU against, 617
resting cells in, with special emphasis on recycling, 1861
solid, comparative physiologic dispositions of 5-FUDR and 5-FU in mice bearing, 845
structure-activity relationships of analogs of cyclophosphamide (especially 4-peroxycyclophosphamide), isophosphamide, trophosphamide, and phosphoramide mustard tested against, 381
studies with 2,5-piperazinedione, 3,6-bis(5-chloro-2-piperidyl)-, dihydrochloride; biochemical and therapeutic effects in L1210 leukemias sensitive and resistant to alkylating agents: comparison with melphalan, cyclophosphamide, and BCNU, 1325
studies with 2,5-piperazinedione, 3,6-bis(5-chloro-2-piperidyl)-, dihydrochloride: kinetic and biologic effects in cultured cells, 1307
L5178Y leukemia, in vivo effects of phenylalanine ammonia-lyase, 261
P815 ascites and solid neoplasms, combination therapy with mitomycin C, 5-FU, and cytosine arabinoside, 1399
P388 leukemia
activity of anthracyclines against an adriamycin-resistant subline of, with special emphasis on cinerubin A, 99
activity of some *Cephalotaxus* alkaloids against, 1157
comparison of 5-FU and ftorafur; therapeutic response and development of resistance in, 1347
comparison of phosphoramide mustards against, 337
effects of *Corynebacterium parvum* alone and in combination with adriamycin in, 823
prostatic adenocarcinoma, effects of cyclophosphamide in the treatment of, 619
P815X2 mastocytoma, proliferative character and growth modes of neoplastic disease as determinants of chemotherapeutic efficacy, using cyclophosphamide, BCNU, and adriamycin, 1761
Sarcoma 45, antitumor activity of 1,2-bis diazoacetyl ethane in, 1601

Sarcoma 180
preliminary studies of toxicities and responsiveness of, to DDMP alone and combined with citrovorum factor, 547
solid and ascitic, antitumor activity of 4-demethoxy-daunorubicin, 4-demethoxy-7,9-diepidaunorubicin, and their β anomers in, 829
Schweitz erythromyelosis, toxicity, antitumor activity, and pharmacokinetics of spin-labeled thioTEPA analogs, 1605
TA-3(St) tumor, effects of tumor bearing on the dynamics of host hemopoietic cells, 1781
Walker 256 carcinosarcoma
antitumor activity of 1,2-bis diazoacetyl ethane in, 1601
dissociation of 5-FU uptake from intracellular pH in, 867
toxicity, antitumor activity, and pharmacokinetics of spin-labeled thioTEPA analogs, 1605
Yoshida sarcoma, carcinostatic activity of yemenimycin in, 937

V

Vernolepin, and derivatives, a new plant-derived tumor inhibitor; mechanism of action, 1115
Vernomenin, a new plant-derived tumor inhibitor; mechanism of action, 1115
Vinblastine (NSC-49842)
combined with adriamycin and bleomycin for advanced testicular tumors, 953
combined with adriamycin, bleomycin, and DTIC (ABVD) in the treatment of Hodgkin's disease, 205
combined with adriamycin and procarbazine in a phase II study of small cell carcinoma of the lung, 1263
combined with bleomycin and *cis*-dichlorodiammineplatinum (II) in the treatment of various cancers, phase I study, 91
combined with procarbazine and cytosine arabinoside for reinduction of childhood acute myelocytic leukemia, 1683
Limulus amebocyte lysate assay used to detect the presence of bacterial endotoxin in various lots of, 9
pharmacology of, 1127
plant product in clinical cancer chemotherapy, 1141
Vincristine (NSC-67574)
plus BCNU versus DTIC alone in the treatment of metastatic malignant melanoma, 595
plus bleomycin and adriamycin compared to ICRF-159 alone in non-small cell lung cancer, 947
in combinations with DTIC plus CCNU and DTIC plus BCNU in the treatment of metastatic malignant melanoma, 601
combined with adriamycin and DTIC or actinomycin D and cyclophosphamide in the treatment of advanced sarcomas: a comparative clinical trial with methyl-CCNU alone, 1385
combined with BCNU and DTIC in the treatment of metastatic cutaneous malignant melanoma, 1381
combined with cyclophosphamide and methotrexate in the treatment of soft tissue sarcomas, 205
combined with cyclophosphamide, methotrexate, and 5-FU following bleomycin alone in the treatment of non-oat cell lung cancer, 61
combined with cyclophosphamide; summary of clinical results of a phase II study in patients with lymphoreticular tumors by the so-called synchronization therapy, 1959
combined with DTIC and BCNU in the treatment of malignant melanoma, 205
combined with DTIC and BCNU; review of activity in malignant melanoma, 1141
combined with DTIC and BCNU, and DTIC and hydroxyurea in the treatment of advanced malignant melanoma, 33
combined with DTIC, BCNU, and hydroxyurea versus the 3 drugs alone in disseminated melanomas, 189
combined with 5-FU, DTIC, and BCNU in the treatment of advanced colorectal cancer, 29
combined with mechlorethamine, prednisone, and procarbazine (MOPP) in the treatment of Hodgkin's disease, 205
combined with methyl-CCNU and 5-FU in the treatment of adenocarcinoma and large cell carcinoma of the lung, 1393
combined with methyl-CCNU and weekly 5-FU in advanced colorectal cancer, 1597
combined with prednisone and L-asparaginase in a study of cytosine arabinoside synchronization of leukemic cells, for remission induction in advanced acute leukemia in children, 591
combined with radiotherapy, cyclophosphamide, and methotrexate in the treatment of extensive oat cell carcinoma, 221
plus cyclophosphamide, 5-FU, and methotrexate and combined with adrenalectomy and oophorectomy in patients with breast cancer, 857
plus cyclophosphamide and methotrexate compared to VP-16-213 alone and vincristine plus bleomycin and adriamycin for advanced small cell lung cancer, 949
effects of, alone or combined with cyclophosphamide and prednisone on some hepatic oxidations and conjugations, 1285
effects of: rapid methods for utilizing cell kinetics for treatment in the C3H/He spontaneous mammary tumor, 1913
plus 5-FU, cyclophosphamide, methotrexate, and citrovorum factor and combined with hormonal therapy in the treatment of disseminated breast cancer, 85
investigations on kinetic data and reproducibility concerning the pharmacologic modification of Ehrlich ascites tumor cell proliferation after, 1959
Limulus amebocyte lysate assay used to detect the presence of bacterial endotoxin in various lots of, 9
pharmacology of, 1127
phase II study of, combined with DTIC and BCNU with or without chlorpromazine in the treatment of disseminated melanomas, 189
phase II study with, combined with 5-FU, methotrexate, cyclophosphamide, and prednisone in the treatment of advanced breast cancer: 2 years' followup, 107
plant product in clinical cancer chemotherapy, 1141

in the treatment of small cell anaplastic lung cancer, 239
used sequentially with cyclophosphamide, bleomycin, methotrexate, adriamycin, and methyl-CCNU in the treatment of advanced, recurrent, squamous cancer of the head and neck, 103
used sequentially with hydroxyurea to enhance the degree of cell synchrony in animal tumors, 1959
Vitamin E (α-tocopherol) (NSC-82623)
amelioration of toxicity from adriamycin by, 961
bis-chloroethyl derivatives of, as potential agents against cancer, 217
VM-26 (NSC-122819)
phase I–II trial in the treatment of children with late-stage leukemia, 265
plant product in clinical cancer chemotherapy, 1141
pharmacology of, 1127
VP-16-213 (NSC-141540)
comparison of the biologic activity of, given iv and orally in capsules or drink ampules, 1377
oral solution, phase I clinical trial of, 943
pharmacology of, 1127
phase II evaluation of, with cytembena in advanced breast cancer, 633
phase II study of, versus dianhydrogalactitol in metastatic malignant melanoma, 1681
phase II study in colorectal cancer, 1247
plant product in clinical cancer chemotherapy, 1141
survival and cycle-progression delay of human lymphoma cells in vitro exposed to, 1295
in the treatment of acute leukemia, 967
versus polychemotherapy (vincristine plus cyclophosphamide and methotrexate; vincristine plus bleomycin and adriamycin) in advanced small cell lung cancer, 949

W

Walker 256 carcinosarcoma *see* Tumor systems in animals

X

X-ray crystallographic studies, of cyclophosphamide derivatives, 517

Y

Yeast mutants, with distorted cell membranes, as tests in the screening for antitumor antibiotics, 637
Yemenimycin, carcinostatic activity of, in animal tumors, 937
Yoshi 864 (1-propanol, 3,3′-iminodi-, dimethanesulfonate [ester], hydrochloride; NSC-102627), survival and cycle-progression delay of cultured human lymphoma cells treated with, 1637
Yoshida sarcoma *see* Tumor systems in animals

Author Index

A

Abbasi MM, 1671
Abbott BJ, 1007
Adams K, 1743
Adams T, 269
Adamson DJ, 1307
Adamson RH, 217, 555, 563, 1127
Adler D, 1959
Ahmann DL, 633, 747, 1385, 1681
Aisner J, 41
Alabaster O, 1981
Alarcon RA, 327
Alberto P, 281
Alberts DS, 1981
Alikpala A, 1937
Allen LM, 69, 445, 451
Amery WK, 217
Anderson T, 761, 801
Andrews NC, 269
Arcamone F, 829
Arlin Z, 1937
Armitage JO, 585
Aroesty J, 1723
Asal NR, 857
Ashby R, 477
Aungst CW, 277
Avadhani NG, 471, 617
Azzarelli A, 205

B

Bain E, 579, 1982
Baisch H, 1983
Bajetta E, 205
Bakemeier RF, 739
Baker LH, 91, 199, 733, 1369, 1389, 1633
Balcerzak S, 199
Band PR, 1431
Barclay AS, 1081
Barlogie B, 1295, 1637, 1707, 1981
Barlow JJ, 527
Barranco SC, 1799
Bartolucci A, 781
Bartošek I, 395
Baserga R, 1811, 1819
Basler GA, 875
Basuk P, 1984
Bateman JR, 953, 1251
Bear RA, 1400
Bearden JD III, 1679
Beazley RW, 1437
Beisler JA, 1671
Bellet RE, 595, 1395
Belvedere G, 493
Benckhuysen C, 369
Benjamin RS, 199, 289
Bennett JM, 625, 739, 925, 939
Beretta G, 33, 205, 1231
Bergevin PR, 293
Bernardi L, 829
Bernath AM, 1393
Bernheim J, 1273
Bernheim JL, 1986
Bhuyan BK, 1813
Bichel P, 1861
Bick RL, 269
Billings A, 1225
Bingel AS, 1171
Bird GG, 1267
Bisel HF, 633, 1385, 1681
Bitran JD, 221, 1225
Blanco M, 1
Block JB, 295
Blom J, 1593
Bloomfield CD, 1683
Blumenschein GR, 199, 289
Bodey GP, Sr, 199
Bodurtha AJ, 595
Bolan G, 1421
Boldrey EB, 243
Bollag W, 281
Bonadonna G, 33, 205, 1231
Bono VH, Jr, 141, 699, 1307
Bottomley RH, 199, 857
Bounous G, 17
Bowdon BJ, 1307
Boyle LE, 61
Brambilla G, 255
Braunschweiger PG, 1913
Brereton HD, 1239
Brindley C, 575
Brock N, 301
Brockman RW, 1307, 1317, 1325
Brodovsky HS, 925
Brodsky I, 625
Brooks JC, 965
Brown AK, 1402
Brown GJA, 1267
Brundrett R, 403
Brunner KW, 1377
Bryan JH, 591
Buck MJ, 1647
Bull F, 953

Bull JM, 1451, 1593
Bullen BR, 1267
Bunch GA, 1267
Bunn PA, 1986
Bunnag B, 1981
Burgess MA, 103, 177, 199, 289
Burns CP, 585
Burns FJ, 1985
Buroker TR, 91, 1277

C

Camerman A, 517
Camerman N, 517
Canetta R, 1231
Cantor RI, 1667
Carbone PP, 193, 625, 739, 925, 939, 1659
Carmo-Pereira J, 107, 1381
Carr DT, 947, 949
Carter G, 1723
Carter RD, 601
Carter SK, 645, 807, 1141
Casazza AM, 829
Cascinelli N, 33
Case DC, Jr, 1217
Catalano RB, 285, 1395
Cavalli F, 1377
Cavanna M, 255
Cedermark BJ, 235
Celle G, 255
Chabner BA, 615
Chadwick DP, 1663
Chadwick M, 845
Chan KK, 1611
Chang C, 845
Charest MC, 881
Chen FP, 1627
Christenson GM, 1171
Clarkson BD, 1217, 1819, 1937
Coccia PF, 1683
Cohen MH, 445, 1393
Cohen RJ, 1257
Coles DT, 947
Colman M, 221, 1225
Colombo T, 395
Colsky J, 925, 939
Coltman CA, Jr, 199, 1679
Colvin M, 403
Comis RL, 165
Coon FB, 999
Cooney DA, 1493
Cooper MR, 1687
Correa J, 1277
Costa FO, 107
Costanzi JJ, 189
Costello W, 193
Cox PJ, 299, 321, 483
Crafts DC, 243, 541
Creagan ET, 1385
Creaven PJ, 69, 445, 451
Creech RH, 285, 625, 925, 1395
Crissman HA, 1729, 1982
Cristofalo VJ, 1985
Cronkite EP, 1871
Crooke ST, 1633
Culliton P, 1285
Cummings FJ, 625
Cysyk RL, 555, 563

D

Dalcq JM, 85
Danova LA, 933
Dar'yalova SL, 1487
Davis L, 477
Davis RD, 1493, 1675
Day KJ, 1813
De Jager RL, 1373
De Lena M, 205
De Wasch G, 1273
Dedrick RL, 889
Deinard A, 903
Delaney WE, 1984
Derriks R, 85
de Ruiter J, 465
Desaive C, 1819
Desner MR, 571
Desser RK, 221, 1225
Devos JM, 91
Dewhurst BB, 477
DeMeester TR, 1225
DeVita VT, Jr, 153, 761
Di Marco A, 829
Didolkar MS, 235
Djachkovskaya RF, 1601, 1605
Djobadze M, 1986
Dodero M, 255
Doering M, 1959
Dombernowsky P, 239, 943, 1263, 1861
Donaldson MH, 265
Donelli MG, 395, 493
Dorfman RF, 781
Dorian R, 1986
Dorick DM, 547
Douglass HO, Jr, 769, 965, 1659
Douros JD, 1069
Draeger U, 309, 355, 423, 509
Drewinko B, 1295, 1619, 1637, 1707, 1981
Driscoll JS, 1493, 1671
Durant JR, 781
Durie BGM, 77

E

Eagan RT, 115, 633, 947, 949, 1385
Edelstein M, 1925
Edlis HE, 575
Edmonson JH, 625, 633, 925, 1385, 1681

Einhorn LH, 103
El Dareer SM, 1627
El-Aaser AA, 937
El-Merzabani MM, 937
Elashoff RM, 243
Elias EG, 235
Eliot HM, 615
Elkind MM, 1777
Emanuel NM, 1601, 1605
Engstrom PF, 285, 1395
Enot KJ, 243
Espinal R, 477
Ethier MF, 1559
Evans R, 1225
Ezdinli EZ, 739, 925

F

Falkson G, 220, 955, 1593, 1655
Falkson HC, 220
Farmer PB, 299, 483
Farnsworth NR, 1171
Farquhar D, 149
Fauvie KA, 1675
Fenselau C, 403
Filov VA, 933
Finley J, 1982
Fisher JI, 1251
Fisher RI, 153
Fleischman RW, 1559
Fletcher WS, 601, 813
Folk RM, 1585
Folkers K, 223
Fong HHS, 1171
Ford SS, 1986
Forrest APM, 1461
Fortner C, 41
Fortuny IE, 903
Fossieck BE, 1393
Foster AB, 483
Fraile R, 1277
Fraser TJ, 1813
Frei E, 1935
Frelick RW, 269
Fried J, 1819, 1937
Friedman OM, 337
Frigerio A, 493
Frytak S, 633, 947, 949, 1681

G

Galvão Teles A, 107
Gams RA, 781
Gang M, 1347
García-Cañero R, 1
Garibjanian BT, 1335, 1347
Garvey MB, 1400
Gaston MR, 823, 1335
Gause GF, 637
Gehan EA, 713, 733
Gennari L, 1231
Germano G, 281
Gershanovich ML, 933
Gerulath AH, 149
Gessner T, 1285
Giardino P, 829
Gilby ED, 483
Giles GR, 1267
Golbey RB, 1373
Gold J, 964
Goldfeder A, 1985
Goldin A, 99, 823, 1335, 1347
Golomb FM, 601
Golomb HM, 221, 1225
Gonzalez-Vitale JC, 917
Gorshein D, 963
Gosálvez M, 1
Gottlieb JA, 103, 177, 199, 215, 289
Goudsmit A, 575
Grabstald H, 917
Grage TB, 601, 813
Gray JW, 1981, 1984
Greco FA, 1239
Green C, 1619
Greenberg SD, 1691
Greenspan EM, 925
Griem M, 1225
Grove GL, 1985
Guaitani A, 395
Guarino AM, 1675
Gurtoo HL, 1285
Gurucharri-Lloyd C, 1
Gutterman JU, 177, 535

H

Haas CD, 611
Hahn GM, 1705, 1791
Hahn RG, 115, 633, 729, 1247, 1385, 1681
Hainau B, 239
Hall R, 1267
Hall SW, 289
Hamilton T, 1461
Hamlin R, 293
Hanjura GL, 277
Hanley J, 1659
Hansel J, 617
Hansen HH, 239, 943, 1263
Hansen R, 1647
Harada M, 361
Harari J, 1982
Hartmann NR, 1861
Hartwell JL, 1031
Hayes FA, 1841
Henderson JF, 1567
Henderson M, 1633
Herman EH, 1663
Hersh EM, 177, 535

Heuson JC, 1463
Hill DL, 1627
Hill GJ II, 183, 601
Hilton J, 725
Hirte WE, 251
Ho M, 1400
Hoge AF, 857
Hohorst H-J, 309, 355, 415, 423, 429, 509
Hollister M, 611
Holmquist JP, 1749
Holoye PY, 61, 1691
Hoogstraten B, 199, 215, 611
Horton J, 625, 925, 939
Hoshino T, 1984
Hoth D, 1437
Houchens DP, 823, 1335
Houghton PJ, 459
Housholder GE, 149
Hrushesky WJ, 639, 966
Hudspith BN, 409
Huff K, 1421
Hult RL, 867
Hutchison DJ, 23

I

Ihde DC, 1393
Israel L, 625, 925, 939, 1431
Iwata T, 361
Izbicki RM, 91, 1369, 1389

J

Jackson RC, 835
Jacobs EM, 953
Jacobs P, 967
Jardine I, 403
Jarman M, 299, 483
Jayaram HN, 1493
Jenkins DE, 1691
Jensen PA, 1251
Jett JH, 579, 1982
Johnson RK, 99, 823, 1335, 1347
Johnson RO, 183
Jones SE, 77
Jordan VC, 1409

K

Kaplan S, 1281
Kardinal CG, 953
Karon M, 9
Kas'yanenko IV, 1483
Kaufman JH, 277, 965
Kendall F, 1819
Kenis Y, 1273
Killmann S-A, 1839
Kiseleva VS, 1487
Kishi T, 223
Kisner DF, 1597
Klaassen DJ, 251
Klein HO, 1959
Klein PJ, 1959
Kline I, 1335, 1347
Knight EW, 939
Knospe WH, 1845
Kondratyev VB, 933
Konovalova NP, 1601, 1605
Korfhagen J, 1281
Kraevskii NA, 1469
Krakoff IH, 1373
Kreis W, 1399
Krementz ET, 183, 601
Kremer WB, 1845
Kress ED, 1985
Krivit W, 1683
Kroner T, 55
Kupchan SM, 1115

L

Lagakos SW, 625, 925, 939
Laiko AV, 637
Lala PK, 1781
Lamerton LF, 1741
Lane M, 907
Langlands AO, 1461
Lanzotti VJ, 61
Larsen V, 29, 943
Larson RE, 867
Laster WR, Jr, 1325
Laucius JF, 595
Laurent C, 85
Lavin PT, 769
Lee BJ III, 1217
Lee RE, 949
Lehane D, 1984
Leimbrock S, 9
Lejeune F, 1273
Lelieveld P, 373
Lenhard RE, Jr, 739
Lennartz KJ, 1959
Lerner HJ, 959, 1431
Leung BS, 1431
Levin VA, 243, 541, 719
Levitt M, 925
Lichtenfeld JL, 41, 571, 963
Lincoln T, 1723
Linden WA, 1983
Lippman M, 1421, 1437, 1451, 1593
Liss RH, 881
Livingston RB, 103, 535, 757, 1141
Lloyd RE, 77
Loo TL, 149, 1619
Lowitz BB, 623
Luckert PH, 619

Luthra YK, 1559
Lutz W, 1461

M

Macdonald JS, 1437, 1597
Maestracci D, 17
Magill GB, 1373
Maksimov IA, 1471
Malaise E, 1887
Malhotra A, 1267
Malyugina LL, 933
Mannes P, 85
Manni A, 1445
Mansour EG, 625, 925
Mardiney MR, Jr, 571
Marmorshtein SIa, 1471
Marshall JS, 1445
Martini A, 395, 493
Maruyama Y, 579, 1982
Masaba JP, 111
Mastrangelo MJ, 595, 1395
Matsumoto S, 361
Matthews MJ, 1393
Mauer AM, 1841
Mavligit GM, 177
McCracken RJ, 973
McFadyen IJ, 1461
McGuire W, 961
McKenna PJ, 1984
McMahon LJ, 77
Mead JAR, 881, 1127
Medenica R, 281
Meiselbaugh D, 219
Mellett LB, 225, 1627
Mendelsohn J, 1986
Metter GE, 183, 601, 813
Meyer RA, 1281
Michel J, 1273
Mikolajczak KL, 1157
Millar JL, 409
Milman HA, 1493
Minna JD, 1393
Minow RA, 215
Minton JP, 601
Mittelman A, 277
Moccio DM, 547
Modica R, 395
Moens R, 85
Moertel CG, 729, 769, 1247, 1659
Montgomery JA, 125, 381, 651
Moon TE, 199
Moore GE, 219
Moore MR, 895
Morabito A, 33
Morgan LR, Jr, 1437
Morgan SK, 591
Morrison P, 1723
Muggia FM, 925
Murphy GP, 277
Murphy SB, 1841
Murphy WK, 289
Muss HB, 1687
Myers CE, 615, 961, 1451
Myers RP, 115
Myles A, 337

N

Nachum R, 9
Nealon TF, 269
Nelson RL, 445, 451
Nesbit ME, 1683
Nichols M, 293
Nicolini C, 1819
Nielsen S, 541
Niemetz J, 575
Nisce L, 1217
Nissen NI, 943
Nivinskaya MM, 1487
Noel J, 1982
Nomura K, 1984
Norpoth K, 437

O

O'Bryan RM, 199, 215
O'Connell MJ, 41, 633, 1681
Oka MS, 1729
Oliveira Costa F, 1381
Oliverio VT, 703
Olweny CLM, 111
Omura GA, 629, 1845
Otter GM, 23
Ovejera AA, 99, 823

P

Pacciarini MA, 395
Pajak TF, 953, 1251
Panasci L, 801
Panettiere FJ, 907
Pannacciulli I, 255
Pantarotto C, 493
Patelli B, 829
Patterson FK, 273
Pavkov KL, 1585
Pearson OH, 1445
Pedersen H, 29
Penn RN, 477
Perdue RE, Jr, 979, 987, 1081
Perevodchikova NI, 1479
Perlia CP, 625, 925, 939
Perlin E, 1593
Perry MC, 1247

Perry S, 1699
Peter G, 309, 355, 429, 509
Peterson SYe, 1473
Petrova AS, 1467
Phelan RS, 1559
Phillips BJ, 321
Picciotto A, 255
Pilch Y, 295
Pimentel P, 107, 1381
Pinedo HM, 889
Pirogov AI, 1471, 1489
Pischer TL, 243
Pittillo RF, 225
Piver MS, 527
Pollard M, 619
Posey LE, 1437
Potmesil M, 1985
Potnis AV, 1402
Poulakos L, 1913
Powell RG, 1157
Pratesi G, 829
Przybylski M, 509
Pullen J, 591

Q

Quagliana JM, 199

R

Rabinovitz M, 1363
Raju MR, 579, 1982
Ramirez G, 813
Ramos A, 1281
Ramsay NKC, 1683
Ransohoff J, 717
Rao SP, 1402
Rapp EF, 251
Ratanatharathorn V, 1369
Reed R, 177
Regelson W, 625, 939, 959
Reggiani P, 829
Reitemeier RJ, 729, 1247
Reynolds RD, 1251
Rice LS, 225
Richards F II, 1687
Richman SP, 535
Rilke F, 1231
Ringsdorf H, 509
Ritter CA, 617
Rivkin SE, 199
Roberts J, 261
Roberts MM, 1461
Rodbard D, 1239
Rodriguez V, 199
Roper P, 1984
Rosenberg SA, 159
Rosenbloom B, 295
Rosenstock JG, 265
Rossof AH, 1679
Rubenstein L, 1225
Rubin J, 947, 949
Ruderman AI, 1475, 1487
Rutman RJ, 471, 617
Ryssel HJ, 1377

S

Saiki JH, 199
Sakurai Y, 937
Saleh AA, 1171
Salmon SE, 77, 789
Samson MK, 91, 1277, 1369, 1389, 1633
Samuels ML, 61
Sanford AH, 1749
Saufferer SM, 1171
Saunders PH, 149
Schabel FM, Jr, 665, 1325
Schaeppi U, 1559
Schein PS, 801, 1437, 1597
Schenken LL, 1761
Schepartz SA, 123, 647, 975
Schiffer CA, 41
Schiffer LM, 1913
Schimpff SC, 41
Schmid FA, 23, 261
Schulten H-R, 501
Schultz MJ, 243
Schutt AJ, 729, 1247
Seager M, 243
Seitz JF, 933
Selawry OS, 925
Selesneva TI, 637
Shackney SE, 1697, 1873, 1986
Shaddix SC, 1317, 1325
Shapiro C, 1225
Shapiro WR, 875
Shaw MT, 857
Shimi IR, 937
Shiratori O, 361
Shnider BI, 625
Sieber SM, 217, 1127
Siegel SE, 9
Sikyewunda W, 111
Simon RM, 1451
Simpson-Herren L, 1749
Sinkovics JG, 199
Sirotnak FM, 547
Slavik M, 213, 795
Smink T, 465
Smith CM, 1567
Smith CR, Jr, 1157
Smith HW, 517
Smith L, Jr, 1597
Smith TL, 61
Smythe T, 1597
Sobrinho TC, 1402
Sohner S, 895

Solomon A, 273
Sonntag RW, 1377
Sonoda T, 273
Sørensen PG, 239
Sörenson S, 1263
Spanjersberg EJ, 369
Sparks FC, 601
Spector R, 913
Spinelli P, 1231
Spjut RW, 979
Spurr CL, 1687
Stanley J, 1743
Starichkov MS, 1487
Starinskii VV, 1471
Statz D, 999
Steel GG, 1743
Steinkamp JA, 1982
Stephens RL, 611
Steuber CP, 591
Stewart HJ, 1461
Stock CC, 23
Stolbach L, 625, 925, 939
Struck RF, 317, 381, 1317
Stukov AN, 933
Suen JY, 535
Sullivan P, 199
Sutow WW, 591
Syrkin AB, 1335
Szekerke M, 347

T

Takai K, 261
Takamizawa A, 361
Talley RW, 907
Tan CTC, 1937
Tancini G, 205, 1231
Taylor DM, 459
Taylor H, 1011
Tew KD, 459
Thake DC, 1585
Theologides A, 903
Thigpen T, 199
Thomas DR, 61, 591
Thomas P, 321
Toal JN, 1363
Tobey RA, 1829
Tochino Y, 361
Tormey DC, 1451, 1593
Tornyos K, 1845
Torres J, 907
Toth IR, 1984
Toya T, 111
Trader MW, 1325
Trakhtenberg AKh, 1489
Trown PW, 1647
Trujillo J, 1445
Tubiana M, 1887
Twentyman PR, 259, 1719

U

Upshall DG, 477

V

Vadlamudi S, 1347
Vaitkevicius VK, 91, 733, 1277
Valeriote F, 1925
Valleron A-j, 1899
Vats T, 591
Velez-Garcia E, 781
Venditti JM, 135, 215, 1347
Veronesi U, 33, 205
Vietti T, 1925
Vistica DT, 1363
Voelcker G, 309, 415, 509
Vogel CL, 895
Vogler WR, 1845
Vyas AC, 293

W

Wagner T, 415, 429
Walker MD, 713, 725, 1257
Wall ME, 1011
Wampler G, 925
Wanek PL, 1982
Wani MC, 1011
Ward JM, 1675
Wasserman TH, 709, 807
Watson E, 1611
Watson RC, 917
Weber G, 835
Weiss AJ, 813, 1667
Wheeler GP, 1307
Wheeler KT, 1984
Wheeler WL, 289
White DR, 1687
White V, 1627
Whitmore WF, 917
Wiernik PH, 41, 571, 963, 1257
Williams JC, 835
Williams M, 1317
Wilson CB, 243, 719
Wilson WL, 183, 269, 813
Wiltshaw E, 55
Winton EF, 895
Wodinsky I, 337
Wolf J, 753
Wolpert MK, 1675
Wong KY, 1281
Woolley C, 225
Woolley PV, 801, 1437, 1597
Wu EC, 1984
Wyatt PJ, 225

Y

Yagoda A, 917
Yamaguchi K, 361
Young CW, 1217
Young DM, 1675
Young RC, 761, 961, 1947

Z

Zaharko DS, 889
Zombor G, 1567
Zucker RM, 1982